WO2011117582A1 - Dendritic cell inhibitory proteins from ticks - Google Patents
Dendritic cell inhibitory proteins from ticks Download PDFInfo
- Publication number
- WO2011117582A1 WO2011117582A1 PCT/GB2011/000419 GB2011000419W WO2011117582A1 WO 2011117582 A1 WO2011117582 A1 WO 2011117582A1 GB 2011000419 W GB2011000419 W GB 2011000419W WO 2011117582 A1 WO2011117582 A1 WO 2011117582A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- seq
- amino acid
- modulatory
- proteins
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 462
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 458
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 182
- 241000238876 Acari Species 0.000 title description 14
- 230000002401 inhibitory effect Effects 0.000 title description 10
- 239000012634 fragment Substances 0.000 claims abstract description 82
- 230000035800 maturation Effects 0.000 claims abstract description 66
- 230000004069 differentiation Effects 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 55
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 235000018102 proteins Nutrition 0.000 claims description 451
- 210000004027 cell Anatomy 0.000 claims description 117
- 150000007523 nucleic acids Chemical class 0.000 claims description 95
- 108020004707 nucleic acids Proteins 0.000 claims description 86
- 102000039446 nucleic acids Human genes 0.000 claims description 86
- 235000001014 amino acid Nutrition 0.000 claims description 83
- 239000013598 vector Substances 0.000 claims description 71
- 150000001413 amino acids Chemical group 0.000 claims description 66
- 102000005962 receptors Human genes 0.000 claims description 65
- 108020003175 receptors Proteins 0.000 claims description 65
- 150000002632 lipids Chemical class 0.000 claims description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 37
- 241001465754 Metazoa Species 0.000 claims description 35
- 201000010099 disease Diseases 0.000 claims description 35
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 30
- 241000238421 Arthropoda Species 0.000 claims description 27
- 238000009826 distribution Methods 0.000 claims description 27
- 206010020751 Hypersensitivity Diseases 0.000 claims description 26
- 235000018417 cysteine Nutrition 0.000 claims description 26
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 26
- 230000013595 glycosylation Effects 0.000 claims description 26
- 238000006206 glycosylation reaction Methods 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 102000004127 Cytokines Human genes 0.000 claims description 19
- 108090000695 Cytokines Proteins 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 230000004913 activation Effects 0.000 claims description 19
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- 235000012000 cholesterol Nutrition 0.000 claims description 15
- 102000019298 Lipocalin Human genes 0.000 claims description 14
- 108050006654 Lipocalin Proteins 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 14
- 230000007815 allergy Effects 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 102000003930 C-Type Lectins Human genes 0.000 claims description 12
- 108090000342 C-Type Lectins Proteins 0.000 claims description 12
- 208000035473 Communicable disease Diseases 0.000 claims description 12
- 208000026935 allergic disease Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 150000001841 cholesterols Chemical class 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 206010052779 Transplant rejections Diseases 0.000 claims description 8
- 230000001861 immunosuppressant effect Effects 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 7
- 229960003957 dexamethasone Drugs 0.000 claims description 7
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 7
- 235000005282 vitamin D3 Nutrition 0.000 claims description 7
- 239000011647 vitamin D3 Substances 0.000 claims description 7
- 229940021056 vitamin d3 Drugs 0.000 claims description 7
- 208000030090 Acute Disease Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 208000037976 chronic inflammation Diseases 0.000 claims description 6
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000009610 hypersensitivity Effects 0.000 claims description 6
- 230000002519 immonomodulatory effect Effects 0.000 claims description 6
- 239000012678 infectious agent Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 5
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 229930182558 Sterol Natural products 0.000 claims description 4
- 239000013566 allergen Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 238000009396 hybridization Methods 0.000 claims description 4
- 230000008086 immune related sensitivity Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 235000003702 sterols Nutrition 0.000 claims description 4
- 208000035145 Arthropod-borne disease Diseases 0.000 claims description 3
- 241001378688 Bothriocrotoninae Species 0.000 claims description 3
- 241001378698 Haemaphysalinae Species 0.000 claims description 3
- 241001378696 Hyalomminae Species 0.000 claims description 3
- 241001194133 Nuttalliellidae Species 0.000 claims description 3
- 241001378697 Rhipicephalinae Species 0.000 claims description 3
- 102000026898 cytokine binding proteins Human genes 0.000 claims description 3
- 108091008470 cytokine binding proteins Proteins 0.000 claims description 3
- 150000003432 sterols Chemical class 0.000 claims description 3
- 241001378687 Amblyomminae Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 241000238681 Ixodes Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 85
- 229940024606 amino acid Drugs 0.000 description 49
- 230000027455 binding Effects 0.000 description 34
- 150000001875 compounds Chemical class 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 32
- 230000005764 inhibitory process Effects 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 230000000875 corresponding effect Effects 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 241000894007 species Species 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 239000002243 precursor Substances 0.000 description 14
- 230000028993 immune response Effects 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 230000001419 dependent effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000000692 anti-sense effect Effects 0.000 description 11
- 108700005078 Synthetic Genes Proteins 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 150000001768 cations Chemical class 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 102000014914 Carrier Proteins Human genes 0.000 description 7
- 108010078791 Carrier Proteins Proteins 0.000 description 7
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 7
- 150000001720 carbohydrates Chemical group 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000003296 saliva Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241001481703 Rhipicephalus <genus> Species 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000003827 upregulation Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000000139 costimulatory effect Effects 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 208000024908 graft versus host disease Diseases 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 5
- 108010000241 Arthropod Proteins Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229930186217 Glycolipid Natural products 0.000 description 4
- 108010015899 Glycopeptides Proteins 0.000 description 4
- 102000002068 Glycopeptides Human genes 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000238890 Ornithodoros moubata Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000033289 adaptive immune response Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000004576 lipid-binding Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000007465 Giant cell arteritis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010066476 Haematological malignancy Diseases 0.000 description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 3
- -1 IFNa Proteins 0.000 description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 3
- 206010021263 IgA nephropathy Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 241001481704 Rhipicephalus appendiculatus Species 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 102000007863 pattern recognition receptors Human genes 0.000 description 3
- 108010089193 pattern recognition receptors Proteins 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229920002704 polyhistidine Polymers 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000012289 standard assay Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 241000238682 Amblyomma americanum Species 0.000 description 2
- 241001480735 Amblyomma cajennense Species 0.000 description 2
- 241001480736 Amblyomma hebraeum Species 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 241000239223 Arachnida Species 0.000 description 2
- 241001480752 Argas persicus Species 0.000 description 2
- 241001480754 Argas reflexus Species 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 241000258924 Ctenocephalides felis Species 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241001480819 Dermacentor andersoni Species 0.000 description 2
- 241000227772 Dermacentor marginatus Species 0.000 description 2
- 241000577477 Dermacentor reticulatus Species 0.000 description 2
- 241001480793 Dermacentor variabilis Species 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 241000233007 Haemaphysalis inermis Species 0.000 description 2
- 241000179419 Haemaphysalis leachi Species 0.000 description 2
- 241000227776 Haemaphysalis punctata Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 241000750137 Hyalomma anatolicum anatolicum Species 0.000 description 2
- 241001480805 Hyalomma dromedarii Species 0.000 description 2
- 241000591667 Hyalomma marginatum marginatum Species 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241001480840 Ixodes hexagonus Species 0.000 description 2
- 241001480847 Ixodes persulcatus Species 0.000 description 2
- 241001480843 Ixodes ricinus Species 0.000 description 2
- 241000238703 Ixodes scapularis Species 0.000 description 2
- 241001378689 Ixodinae Species 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241000270322 Lepidosauria Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000018656 Mitogen Receptors Human genes 0.000 description 2
- 108010052006 Mitogen Receptors Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000092202 Ornithodoros erraticus Species 0.000 description 2
- 241000985247 Ornithodoros savignyi Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 241001674048 Phthiraptera Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 2
- 241000949016 Rhipicephalus bursa Species 0.000 description 2
- 241001481696 Rhipicephalus sanguineus Species 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 208000001117 Theileriasis Diseases 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 208000035056 Tick-Borne disease Diseases 0.000 description 2
- 208000003441 Transfusion reaction Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 206010043207 temporal arteritis Diseases 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 208000016523 tick-borne infectious disease Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010001324 Adrenal atrophy Diseases 0.000 description 1
- 241000256111 Aedes <genus> Species 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241001480834 Amblyomma variegatum Species 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 241000256182 Anopheles gambiae Species 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 241001144661 Apis mellifera iberica Species 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000000104 Arthus reaction Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000011594 Autoinflammatory disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 244000089654 Betula populifolia Species 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 201000002829 CREST Syndrome Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100025597 Caspase-4 Human genes 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 208000010007 Cogan syndrome Diseases 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000000307 Crimean Hemorrhagic Fever Diseases 0.000 description 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 1
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 241000256054 Culex <genus> Species 0.000 description 1
- 241000256057 Culex quinquefasciatus Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000029012 Dowling-Degos disease Diseases 0.000 description 1
- 208000021866 Dressler syndrome Diseases 0.000 description 1
- 208000016974 Eales' disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 208000004332 Evans syndrome Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101001066288 Gallus gallus GATA-binding factor 3 Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 241000257324 Glossina <genus> Species 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000933112 Homo sapiens Caspase-4 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241001194135 Ixodoidea Species 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 102100030635 Leukocyte elastase inhibitor Human genes 0.000 description 1
- 101710091916 Leukocyte elastase inhibitor Proteins 0.000 description 1
- 208000022435 Light chain deposition disease Diseases 0.000 description 1
- 208000020647 Light chain disease Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 231100000757 Microbial toxin Toxicity 0.000 description 1
- 241000403354 Microplus Species 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100381525 Mus musculus Bcl6 gene Proteins 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000004788 Pars Planitis Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000255129 Phlebotominae Species 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000238711 Pyroglyphidae Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241001480837 Rhipicephalus annulatus Species 0.000 description 1
- 241000864246 Rhipicephalus decoloratus Species 0.000 description 1
- 241000238680 Rhipicephalus microplus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 241000256103 Simuliidae Species 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 241000255628 Tabanidae Species 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 241000223779 Theileria parva Species 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 101100357018 Trypanosoma brucei brucei RNR2 gene Proteins 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000011312 Vector Borne disease Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960004784 allergens Drugs 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000012592 cell culture supplement Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 230000000486 effect on maturation Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002190 fatty acyls Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 229940046533 house dust mites Drugs 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003591 leukocyte elastase inhibitor Substances 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 229920000344 molecularly imprinted polymer Polymers 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 125000000830 polyketide group Chemical group 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 1
- 150000003135 prenol lipids Chemical class 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003313 saccharo lipids Chemical class 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000024161 type IIb hypersensitivity Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229940075601 voluven Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002578 wasp venom Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to dendritic cell (DC) modulatory proteins.
- DC dendritic cell
- the invention relates to proteins which modulate, and preferably inhibit, the differentiation and/or maturation of mammalian DCs and to the identification of motifs and features of such proteins which may be important for their structure and function.
- proteins can be isolated from arthropod saliva, and more specifically from tick saliva.
- the invention also relates to the use of such proteins in therapy, and specifically to the use of such proteins in treating autoimmune disorders, allergies, autoinflammatory diseases and other immune-related sensitivities, also known as hypersensitivity diseases, transplant reactions such as transplant rejection and graft- versus-host disease, infectious diseases including those transmitted by ticks, cancers including haematological malignancies, and acute and chronic inflammatory diseases including inflammation associated with the aforementioned diseases.
- the mammalian, and particularly the human, immune system is comprised of two arms, the innate and the adaptive immune systems.
- the cells of the innate immune system recognise, and respond to, infectious agents in a generic manner.
- the innate immune system is a vital immediate barrier to infection, it does not confer specific, long- lasting protection against foreign entities, such as invading pathogens.
- the cells of the adaptive immune system recognise specific foreign entities, and induce immunological memory to these specific entities in the host.
- DCs interact with components of the innate immune system soon after infection by a pathogen and also form a central part of the mammalian adaptive immune response.
- DCs differentiate from precursor cells into immature DCs. Immature DCs are present throughout the body and, although other cells of the immune system also participate in this role, they are the major cell type responsible for initiation of adaptive immune responses, primarily through their capacity to trigger T cell activation.
- Immature DCs constantly sample their surrounding environment for infectious agents such as viruses, bacteria and parasites, through pattern recognition receptors (PRRs) such as toll-like receptors (TLRs) which recognise specific chemical signals on the foreign entity, e.g. on a pathogen's surface.
- PRRs pattern recognition receptors
- TLRs toll-like receptors
- the immature DC undergoes several changes collectively termed 'maturation' and starts to develop into a mature DC.
- the maturing DC up-regulates expression of major histocompatability complex (MHC), and MHC- related molecules such as CD1, which bind the foreign entity-derived peptides and glycopeptides, and lipids or glycolipids, respectively, and allow them to be displayed on the DC surface.
- MHC major histocompatability complex
- CD1 cell surface receptors known as costimulatory molecules including CD80, CD86 and CD40, which act as co- receptors for T lymphocyte activation.
- the DC begins to migrate to lymphoid tissues such as the lymph nodes and/or spleen, following chemotactic signals.
- lymphoid tissues such as the lymph nodes and/or spleen, following chemotactic signals.
- the DC activates T lymphocytes, by presenting them with the peptides and glycopeptides or lipid fragments derived from the foreign entity and delivering the appropriate co-stimulatory signals.
- T lymphocytes are responsible for propagating the adaptive immune response.
- the foreign entity may be a pathogen, an allergen, a transplantation antigen such as a major transplant antigen or a minor transplant antigen, a blood group antigen or, in the case of an autoimmune response, a self-antigen incorrectly identified by the body as foreign.
- mature DCs are involved in T cell regulation, such as polarisation of helper T cells into Thl, Th2, Thl7 or regulatory (Treg) cells, the activation of cytotoxic T cells, and modulation of T cell homing, e.g. into the skin or gut and other mucosal sites.
- T cell regulation such as polarisation of helper T cells into Thl, Th2, Thl7 or regulatory (Treg) cells, the activation of cytotoxic T cells, and modulation of T cell homing, e.g. into the skin or gut and other mucosal sites.
- DC modulators may be useful in the treatment of autoimmune and other inflammatory diseases (Subklewe et al, Human Immunology, 2007, 68(3), 147-155). It has also been suggested that DC modulators may be useful in the treatment of cancer (Banchereau, J. et al, Ann N Y Acad Sci, 2003, 987, 180-187 and Figdor, C.G. et al, Nature medicine, 2004, 10 (5), 475-480). Ticks and some other haematophagous arthropods attach to their hosts, including mammals such as humans, and feed for extended periods of time.
- haematophagous arthropods deliver to the hosts can potentially induce host immune responses. Such responses may be deleterious to the arthropods and therefore the arthropods may need to suppress them. Given the central role of DCs in triggering immunity, it may be advantageous to the arthropods to produce proteins that inhibit their function.
- Haematophagous arthropods, and particularly ticks, may inhibit the host's immune system by inoculating the host with a variety of anti-inflammatory and immunomodulatory components (Ribeiro et al, Infectious Agents and Disease, 1992, 4(3), 143 - 152).
- immunomodulatory molecules have been identified in tick saliva, including a homologue of macrophage migration inhibitory factor (MIF) (Jaworski et al, Insect Molecular Biology, 2001, 10(4), 323-331), a homologue of leukocyte elastase inhibitor which is secreted by human macrophages, monocytes and neutrophils (Leboulle et al, The Journal of Biological Chemistry, 2002, 277(12), 10083 - 10089), glycosylated protein p36, which is thought to suppress mitogen driven in vitro proliferation of murine spleen cells (Bergman et al, Journal of Parasitology, 2000, 86, 516 - 525), B cell inhibitory protein (BIP) (Hannier et al, Immunology, 2004, 1 13, 401 - 408), and B cell inhibitory factor (BIF) (Yu et al, Biochemical and Biophysical Research Communications, 2006, 343, 585 - 590).
- MIF macrophag
- Salpl5 is a protein present in tick saliva which has been found to act on immature human DCs (Anguita et al, Immunity, 2002, 16, 849 - 859 and Hovius et al, Vector borne and Zoonotic diseases, 2007, 7(3), 296 - 302).
- assays involving the incubation of immature human DCs with Salpl5 in the presence of an immune stimulus have shown that Salpl5 does not inhibit the upregulation of costimulatory molecules (e.g. CD86). Salpl5 does not therefore inhibit the maturation of human DCs.
- Prostaglandin E 2 is a non-protein molecule present in tick saliva that may modulate the activity of immature murine DCs, but has a minimal effect on maturation of these murine DCs (Sa-Nunes et al, The Journal of Immunology, 2007, 179, 1497 - 1505). PGE 2 is capable of enhancing the maturation of human DCs but there is no evidence that it can act to inhibit the differentiation and maturation of human DCs.
- tick saliva and salivary gland extract may possess the ability to modulate the differentiation and maturation of murine DCs (Cavassani et al, Immunology, 2005, 114, 235 - 245, and Skallova et al, Journal of Immunology, 2008, 180, 6186-6192).
- a DC modulatory molecule has been isolated from the tick Rhipicephalus appendiculatus, and shown to modulate the differentiation and maturation of mammalian DCs (PCT/GB2009/002219). In particular, this molecule has been shown to alter the development of differentiation cultures by inhibiting upregulation of CD la and downregulation of CD 14, a signature of differentiation into DCs, and to inhibit T cell proliferation.
- This molecule is known as Japanin (SEQ ID NO: 8) and a limited number of homologues of Japanin have also been identified in other tick species (SEQ ID NOs: 10, 12, 14 and 16). It would be advantageous to identify further homologues of Japanin which act as DC modulators for therapeutic purposes. It would also be advantageous to identify the key motifs and features of such DC modulatory proteins which are responsible for their function.
- the present invention provides a DC modulatory protein, wherein said protein modulates, and preferably inhibits, mammalian DC differentiation and/or maturation, and preferably includes at least one of a number of conserved motifs and features that have been identified across a number of such proteins, and which are believed to be important to the function of such proteins.
- the present invention includes a DC modulatory protein, wherein said protein modulates DC differentiation and/or maturation and comprises:
- the present invention provides a dendritic cell (DC) modulatory protein, wherein said protein modulates mammalian DC differentiation and maturation and comprises:
- the protein of the invention may consist of the amino acid sequence of any one of a) SEQ ID NOs: 2, 25 or 28 (RaA); b) SEQ ID NOs: 4, 26 or 29 (RaB); or c) SEQ ID NOs: 6, 24 or 27 (Rsl). In one embodiment the protein of the invention may consist of the amino acid sequence of any one of SEQ ID NOs: 2, 4 or 6.
- the proteins of the invention "modulate”, i.e. alter, or “inhibit”, i.e. reduce, the differentiation and/or maturation of mammalian DCs.
- the proteins of the invention “modulate”, i.e. alter, or “inhibit”, i.e. reduce, both the differentiation and maturation of mammalian DCs. In one embodiment, these may be human DCs.
- the proteins of the invention may additionally modulate or inhibit the differentiation and/or maturation of reptile and/or fish DCs as well as mammalian DCs. Suitable assays for assessing modulation or inhibition of DC differentiation and maturation are described below.
- the protein of the invention reduces both DC differentiation and maturation by at least 20% as measured, for example, by the assays discussed below.
- the inhibition of DC differentiation and/or maturation may be 30%, 40%, 50%, 60%, 70%, 80%, 90% or more.
- DC differentiation is meant the development of a cell precursor, such as a bone marrow derived progenitor or a blood monocyte, into an immature DC.
- Modulation, for example inhibition, of DC differentiation can be assessed phenotypically and, ultimately functionally, using standard assays known in the art. These include the assessment of CD 14 and CD la expression, which are regulated during DC differentiation. Further methods for assessing the inhibition of DC differentiation will be known to a person skilled in the art.
- Inhibition of phenotypic differentiation of precursors into immature DCs can be assessed using cellular markers whose expression is altered as the precursor cell differentiates into an immature DC.
- monocytes are DC precursors which are CD14-positive and CD la-negative.
- Immature DCs are CD14-low, and in some embodiments CD 14- negative, and CD la-positive.
- differentiation of monocytes into immature DCs may be detected by a decrease in CD 14 and an increase in CD la.
- Inhibition of differentiation of precursor cells into immature DCs by the proteins of the invention may be detected by the continued presence of precursor cells that are CD14-high, and in some embodiments CD14-positive, and CD la-negative.
- Typical T cell proliferation assays include the allogeneic mixed leukocyte reaction (MLR) and oxidative mitogenesis.
- DC maturation is meant the process which occurs after a precursor cell has differentiated into an immature DC. Specifically, this term relates to the changes which occur when a differentiated, immature DC encounters a stimulus, and is converted into a mature DC.
- the stimulus may be a component of an infectious agent such as a pathogen, which is sensed via PRR such as TLR, certain cytokines which act through cytokine receptors, and/or specialised cell surface molecules of other cell types such as CD 154 of activated T cells.
- PRR such as TLR
- cytokines which act through cytokine receptors
- specialised cell surface molecules of other cell types such as CD 154 of activated T cells.
- the changes associated with maturation of immature DCs typically include the up-regulation of expression of costimulatory molecules e.g.
- CD80 and CD86 and the presentation of antigens from the pathogenic-derived component on the DCs surface, typically as peptide-MHC and lipid-CDl complexes. Maturation of immature DCs may also be associated with migration of the DC to the secondary lymphoid tissues.
- the proteins of the invention may act to modulate or inhibit any of these changes associated with maturation of immature DCs.
- the ability of the molecules of the invention to inhibit immature DC maturation may thus be assessed by their ability to decrease the expression of CD86 and/or CD80 and/or MHC molecules.
- the ability of the proteins of the invention to inhibit immature DC maturation may be assessed by their ability to decrease the expression and/or the secretion of TNFa.
- the ability of the proteins of the invention to modulate DC maturation may be assessed by their ability to increase levels of B7 homolog 1 (B7-H1 or C274) expression.
- the ability of the proteins of the invention to inhibit DC maturation may optionally be assessed following poly(I:C), LPS or ⁇ stimulation.
- the ability of the proteins of the invention to inhibit DC maturation may optionally be assessed following CD40L, IFNa, or a TLR7 or TLR8 ligand (e.g. CL097) stimulation. Further methods for assessing the inhibition of immature DC maturation will be known to a person skilled in the art.
- the proteins of the invention act to modulate, and preferably inhibit, differentiation of precursor cells into immature DCs and to modulate, and preferably inhibit, the subsequent maturation of immature DCs into mature DCs.
- modulation or inhibition of both DC differentiation and maturation is likely to have downstream modulatory effects on the immune system as a whole, as described in more detail below.
- T lymphocytes Prior to activation by an antigen presenting cell, T lymphocytes are referred to as "naive". Each T lymphocyte is specific for a particular antigen, and can only be activated by a 'specialised' antigen presenting cell, such as a DC, which is presenting this cognate antigen.
- Conventional T lymphocytes recognise the antigen-MHC complex through the T cell receptor (TCR), which is a heterodimeric structure, comprising a and ⁇ chains.
- TCR T cell receptor
- signalling through the TCR in the absence of costimulation, results in a state of antigen-unresponsiveness or anergy, or abortive activation and cell death.
- T lymphocyte activation is meant activation of helper T cells, including Thl , Th2, Thl 7 or Treg cells, and optionally the activation of cytotoxic T cells which is often dependent on prior activation of helper T cells.
- T cell activation may be assessed by methods known in the art.
- T cell activation may be assessed by in vitro assays of cytokine secretion [e.g. interleukin (IL)-2 production] or T cell proliferation triggered by DC (e.g. allogeneic MLR or oxidative mitogenesis) or by in vivo assays of T cell responses to model antigens (e.g. ovalbumin) in normal or transgenic animals using similar assays of T cells isolated ex vivo before and after antigen re-stimulation.
- cytokine secretion e.g. interleukin (IL)-2 production
- DC e.g. allogeneic MLR or oxidative mitogenesis
- model antigens e.g. ovalbumin
- the proteins of the invention will reduce T lymphocyte activation by at least about 20% compared to a standard assay in the absence of a DC differentiation and or maturation inhibiting protein.
- the inhibition of DC differentiation and maturation may reduce T lymphocyte activation by at least about 30%, 40%, 50%, 60%, 70%, 80%, 90% or more.
- the modulation or inhibition of DC differentiation and/or maturation afforded by the proteins of the invention results in a modulation in T lymphocyte regulation.
- the proteins of the invention may modulate the polarisation of T lymphocytes into Thl versus Th2 versus Thl 7 versus regulatory T (Treg) or follicular helper T (Thf) cells. Modulation of T lymphocyte polarisation by the proteins of the invention may be assessed by measuring T-lymphocyte-derived cytokines typically associated with different types of CD4 and CD8 T lymphocytes in in vitro assays.
- Thl cells these include IFN- ⁇ ; for Th2 cells, IL-4, IL-5, and IL- 13; for Thl 7 cells, IL-17; and for Treg cells, IL-10 and TGFp.
- the respective types of CD4 cell can also be assayed by measuring expression of T-bet, GATA-3, ROR- ⁇ - ⁇ or ROR-y-c and FoxP3 respectively, or by measuring expression of Bcl6 for Thf cells.
- the phenotype of the different cells can be assessed phenotypically, e.g. by assessing the chemokine receptors and other phenotypic markers that they express.
- T lymphocytes are one of the major facilitators of the mammalian immune response. Therefore, a reduction in the activation of T lymphocytes by the proteins of the invention or a change in the polarisation of such T lymphocytes, as described above, will result in an overall modulation of the immune response and in particular in changes in the levels of cytokines associated with the immune response.
- the proteins of the invention may have a generally immunosuppressant effect.
- a modulation in the immune response can be measured using any one of a variety of methods known in the art.
- a decrease in, or modulation of, the overall immune response can be measured by looking for a reduction in the levels of pro-inflammatory cytokines produced most rapidly in response to TLR stimulation, e.g. interleukin-1 and tumour necrosis factor a (TNFa), interferon-a, interferon ⁇ , or cytokines such as IL-6 or IL-12 typically produced at intermediate times after infection.
- TNFa interleukin-1 and tumour necrosis factor a
- cytokines such as IL-6 or IL-12 typically produced at intermediate times after infection.
- the proteins of the invention may also lead to an increase in the level of anti-inflammatory cytokines e.g. IL-lO or TGF- ⁇ .
- the proteins of the invention will reduce the levels of proinflammatory cytokines or increase the levels of anti-inflammatory cytokines by at least about 20% compared to a standard assay in the absence of a DC differentiation and/or maturation inhibiting protein.
- the inhibition of DC differentiation and/or maturation may reduce the levels of pro-inflammatory cytokines or increase the levels of anti-inflammatory cytokines by at least about 30%, 40%, 50%, 60%, 70%, 80%, 90% or more.
- An immunosuppressant effect may also be assessed by a variety of other methods, for example a localised reduction in inflammation or a reduction in the size or activity of generated antigen-specific T and B cell pools.
- the proteins of the invention may be isolated from an arthropod.
- An "arthropod” is defined as an animal belonging to the phylum Arthropoda, and includes insects, crustaceans and arachnids. Arthropods are characterised by a segmented body and a hard exoskeleton made of chitin.
- the proteins of the invention may be isolated from a haematophagous arthropod.
- haematophagous arthropod includes all arthropods that take a blood meal from a suitable host. This includes ticks, mites, and insects such as lice, fleas and mosquitoes. They are commonly known as blood feeding arthropods, and these two terms will be used interchangeably throughout this specification.
- the isolated haematophagous arthropod may be a tick.
- tick is the common name given to small arachnids in the superfamily Ixodoidea, which is included within the haematophagous arthropods. Ticks are ectoparasites, and live on the blood of mammals, birds, and reptiles. Ticks may also live on the blood of amphibians.
- ticks There are approximately 900 species of tick, which are found throughout the world. Different tick species are characterised by their preferential habitat and by their geographical distribution. Most tick species can feed on a variety of host species, including humans. As discussed above, arthropods, and particularly ticks may inhibit the host's immune system by inoculating the host with a variety of anti-inflammatory and immunomodulatory components.
- the DC modulatory proteins of the present invention may be isolated from any known tick species, including species within the groups Ixodinae, Bothriocrotoninae, Amblyomrninae, Haemaphysalinae, Rhipicephalinae, Hyalomminae, Nuttalliellidae, Argasinae, Otobinae, Antricolinae, Nothoaspinae and Omithodorinae, for example, any one of the following tick species: Rhipicephalus appendiculatus, Rhipicephalus sanguineus, Rhipicephalus bursa, Amblyomma americanum, Amblyomma cajennense, Amblyomma hebraeum, Amblyomma variegatum, Rhipicephalus (Boophilus) microplus, Rhipicephalus (Boophilus) annulatus, Rhipicephalus (Boophilus) decoloratus, Dermacentor
- the present invention includes homologues and active fragments of proteins having the amino acid sequence of any one of a) SEQ ID NOs: 2, 25 or 28 (RaA); b) SEQ ID NOs: 4, 26 or 29 (RaB); or c) SEQ ID NOs: 6, 24 or 27 (Rsl).
- the present invention includes homologues and active fragments of proteins having the amino acid sequence of any one of SEQ ID NOs: 2, 4 or 6.
- homologue is intended to include reference to paralogues and orthologues of the proteins of the invention disclosed in SEQ ID NOs: 2, 4 and 6, or SEQ ID NOs: 24, 25, 26, 27, 28 or 29 that retain the ability to modulate, and preferably inhibit, the differentiation and/or maturation of DCs.
- Homologues may possess the ability to modulate, and preferably inhibit, the differentiation and/or maturation of DCs, resulting in a decrease in T lymphocyte activation or modulation of T lymphocyte polarisation, as described above.
- the invention includes a protein comprising or consisting of an amino acid sequence having at least 20% sequence identity to any one of SEQ ID NO: 2, 25 or 28. In other embodiments the invention includes proteins comprising or consisting of an amino acid sequence having at least 40%, 50%, 60%, 70%, 80%, 81%, 82%, 85%, 90%, 95%, 98%, 99% or more to any one of SEQ ID NO: 2, 25 or 28. In one embodiment, the invention includes a protein comprising or consisting of an amino acid sequence having at least 20% sequence identity to SEQ ID NO: 2.
- the invention includes proteins comprising or consisting of an amino acid sequence having at least 40%, 47%, 48%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% or more to SEQ ID NO: 2.
- the invention includes a protein comprising or consisting of an amino acid sequence having at least 20% sequence identity to SEQ ID NO: 4, 26 or 29. In other embodiments the invention includes proteins comprising or consisting of an amino acid sequence having at least 40%, 50%, 60%, 70%, 80%, 81%, 82%, 85%, 90%, 95%, 98%, 99% or more to SEQ ID NO: 4, 26 or 29.
- the invention includes a protein comprising or consisting of an amino acid sequence having at least 20% sequence identity to SEQ ID NO: 4. In other embodiments the invention includes proteins comprising or consisting of an amino acid sequence having at least 40%, 50%, 53%, 54%, 60%, 70%, 80%, 85%, 90%, 95%, 98%, 99% or more to SEQ ID NO: 4.
- the invention includes a protein comprising or consisting of an amino acid sequence having at least 20% sequence identity to SEQ ID NOs: 6, 24 or 27. In other embodiments the invention includes proteins comprising or consisting of an amino acid sequence having at least 40%, 50%, 60%, 70%, 80%, 81%, 82%, 85%, 90%, 95%, 98%, 99% or more to SEQ ID NOs: 6, 24 or 27.
- the invention includes a protein comprising or consisting of an amino acid sequence having at least 20% sequence identity to SEQ ID NO: 6. In other embodiments the invention includes proteins comprising or consisting of an amino acid sequence having at least 40%, 50%, 60%, 70%, 80%, 81%, 82%, 85%, 90%, 95%, 98%, 99% or more to SEQ ID NO: 6.
- Homologues of the proteins of the invention also include mutants containing amino acid substitutions, insertions or deletions from the sequences of SEQ ID NOs: 2, 4, 6, 24, 25, 26, 27, 28 or 29 and fragments thereof, provided that the ability to modulate, and preferably inhibit, the differentiation and/or maturation of DCs is retained.
- Mutants may possess the ability to modulate, and preferably inhibit, the differentiation and/or maturation of DCs, resulting in a decrease in T lymphocyte activation or modulation of T lymphocyte polarisation, as described above.
- mutants may possess the ability to modulate, and preferably inhibit, the differentiation and/or maturation of DCs, resulting in an inhibition of the immune response, as described above.
- Mutants thus include proteins containing conservative amino acid substitutions that do not affect the function or activity of the protein in an adverse manner.
- This term is also intended to include natural biological variants (e.g. allelic variants or geographical variations within the species from which the isolated arthropod proteins of the invention are derived).
- Mutants with improved activity in the modulation or inhibition of the differentiation and/or maturation of DCs compared to that of the wild type protein sequence may also be designed through the systematic or directed mutation of specific residues in the protein sequence.
- Homologues may be derived from tick species including but not limited to Rhipicephalus appendiculatus, including Rhipicephalus sanguineus, Rhipicephalus bursa, Amblyomma americanum, Amblyomma cajennense, Amblyomma hebraeum, Ambylomma variegatum, Rhicephalus (Boophilus) microplus, Rhicephalus (Boophilus) annulatus, Rhicephalus (Boophilus) decoloratus, Dermacentor reticulatus, Dermacentor andersoni, Dermacentor marginatus, Dermacentor variabilis, Haemaphysalis inermis, Haemaphysalis leachii, Haemaphysalis punctata, Hyalomma anatolicum anatolicum, Hyalomma dromedarii, Hyalomma marginatum marginatum, Ixodes ricinus, Ixodes persulcatus
- Homologues may also be derived from mosquito species, including those of the Culex, Anopheles and Aedes genera, particularly Culex quinquefasciatus, Aedes aegypti and Anopheles gambiae; flea species, such as Ctenocephalides felis (the cat flea); horseflies; sandflies; blackflies; tsetse flies; lice; and mites.
- mosquito species including those of the Culex, Anopheles and Aedes genera, particularly Culex quinquefasciatus, Aedes aegypti and Anopheles gambiae
- flea species such as Ctenocephalides felis (the cat flea); horseflies; sandflies; blackflies; tsetse flies; lice; and mites.
- homologues may be derived from any known tick species, for example those within the groups Ixodinae, Bothriocrotoninae, Amblyomminae, Haemaphysalinae, Rhipicephalinae (including Hyalomminae), Nuttalliellidae, Argasinae, Otobinae, Antricolinae, and Ornithodorinae.
- homologues may be identified by homology searching of sequence databases, both public and private.
- publicly available databases may be used, although private or commercially-available databases will be equally useful, particularly if they contain data not represented in the public databases.
- Primary databases are the sites of primary nucleotide or amino acid sequence data deposit and may be publicly or commercially available.
- Examples of publicly-available primary databases include the GenBank database (http://www.ncbi.nlm.nih.gov/), the EMBL database (http://www.ebi.ac.uk/), the DDBJ database (http://www.ddbj.nig.ac.jp/), the SWISS-PROT protein database (http://expasy.hcuge.ch/), PIR (http://pir.georgetown.edu/), TrEMBL (http://www.ebi.ac.
- the TIGR databases see http://www.tigr.org/tdb/index.html
- the NRL-3D database http://www.nbrfa.georgetown.edu
- the Protein Data Bank http://www.rcsb.org/pdb
- the NRDB database ftp://ncbi.nlm.nih.gov/pub/nrdb/README
- the OWL database http://www.biochem.ucl.ac.uk/bsrn/dbbrowser/OWL/
- the secondary databases http://expasy.hcuge.ch/sprot/prosite.html
- PRINTS http://iupab.leeds.ac.
- amino acid sequences of SEQ ID NOs: 2, 4 and 6 may not be full-length sequences.
- the invention thus provides that further amino acids may be present at the N-terminus and/or the C-terminus of proteins comprising the amino acid sequences of SEQ ID NOs: 2, 4 or 6.
- the invention includes proteins comprising the addition of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 amino acid at the N-terminus and/or the C-terminus of the sequences of any one of SEQ ID NOs: 2, 4 or 6.
- amino acid sequences of SEQ ID NOs: 24, 25 and 26 are believed to represent full- length proteins.
- Amino acid sequences of SEQ ID NO: 27, 28 and 29 are predicted to represent the mature proteins (with which is meant the proteins without the signal sequences typical for secretion products).
- the invention also provides that further amino acids may be present at the N-terminus and/or C-terminus of proteins comprising the amino acid sequences of a) SEQ ID NOs: 2, 25 or 28 (RaA); b) SEQ ID NOs: 4, 26 or 29 (RaB); or c) SEQ ID NOs: 6, 24 or 27 (Rsl).
- the invention includes proteins comprising the addition of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 150 or 200 amino acid at the N-terminus and/or the C-terminus of the sequences of any one of a) SEQ ID NOs: 2, 25 or 28 (RaA); b) SEQ ID NOs: 4, 26 or 29 (RaB); or c) SEQ ID NOs: 6, 24 or 27 (Rsl).
- the invention also includes functional equivalents of the proteins of the invention.
- the term "functional equivalent” is used herein to describe any molecule possessing the ability to modulate, and preferably inhibit, the differentiation and/or maturation of DCs in a manner corresponding to proteins of the invention. This includes synthetically produced proteins, synthetic variants of the protein, protein molecules of a different sequence which confer corresponding activity, naturally occuring non-protein molecules with corresponding activity, and synthetic non-protein molecules with corresponding activity. It also includes semi-synthetically produced proteins, semisynthetic variants of the protein and semi-synthetic non-protein molecules with corresponding activity. Also included are antibodies that mimic the ability of proteins of the invention to modulate, and preferably inhibit, the differentiation and/or maturation of DCs.
- functional equivalents possess the ability to modulate, and preferably inhibit, the differentiation and/or maturation of DCs, resulting in a decrease in T lymphocyte activation or modulation of T lymphocyte polarisation, as described above.
- functional equivalents possess the ability to modulate, and preferably inhibit, the differentiation and/or maturation of DCs, resulting in an inhibition of the immune response, as described above.
- homologues may retain one or more of the conserved motifs and features of the DC modulatory proteins of SEQ ID NOs: 2, 4 and 6 or SEQ ID NOs: 24, 25, 26, 27, 28 or 29. As described below, these include a conserved glycosylation site containing sequence, cysteine distribution pattern, CXXW motif, lipid binding ability, and receptor binding ability.
- the proteins of the invention or homologues thereof do not have the amino acid sequence of any one of SEQ ID NOs: 8, 10, 12, 14, or 16. These sequences correspond to SEQ ID NOs: 2, 4, 6, 8 and 10 of PCT/GB2009/002219, respectively.
- the present invention also provides "active fragments" of the proteins of the invention and of homologues of these sequences. Included within this definition are any fragments which retain the ability to modulate or inhibit mammalian DC differentiation and/or modulation.
- fragments are not only fragments of amino acid sequences of SEQ ID NOs: 2, 4 and 6 or SEQ ID NOs: 24, 25, 26, 27, 28 or 29, but also fragments of homologues of this protein, as described above.
- Such fragments of homologues will typically possess greater than 20% identity with fragments of the amino acid sequences of any one of SEQ ID NOs: 2, 4 or 6.
- Said fragments of homologues will typically possess greater than 20% identity with fragments of the amino acid sequence of any one of i) SEQ ID NOs: 2, 25 or 28, ii) SEQ ID NOs: 4, 26 or 29 or iii) SEQ ID NOs: 6, 24 or 27.
- fragments of homologues will display degrees of identity of greater than 30%, 40%, 47%, 48%, 50%, 52%, 53% 60%, 70%, 80%, 81%, 82%, 90%, 95%, 98% or 99%, respectively with fragments of the isolated arthropod proteins of SEQ ID NOs: 2, 4 or 6.
- fragments of homologues will display degrees of identity of greater than 30%, 40%, 47%, 48%, 50%, 52%, 53% 60%, 70%, 80%, 81%, 82%, 90%, 95%, 98% or 99%, respectively with fragments of the isolated arthropod proteins of any one of i) SEQ ID NOs: 2, 25 or 28, ii) SEQ ID NOs: 4, 26 or 29 or iii) SEQ ID NOs: 6, 24 or 27.
- Protein fragments of the invention are preferably active fragments of SEQ ID NOs: 2, 4 or 6 or SEQ ID NOs: 24, 25, 26, 26, 28 or 29 and homologues thereof as described above. These fragments preferably modulate, and more preferably inhibit, the differentiation and/or maturation of DCs. In one embodiment, fragments of the proteins of the invention modulate, and preferably inhibit, the differentiation and/or maturation of DCs resulting in a decrease in T lymphocyte activation or modulation of T lymphocyte polarisation, as described above. In a further embodiment, fragments of the proteins of the invention modulate, and preferably inhibit, the differentiation and/or maturation of DCs, resulting in an inhibition of the immune response, as described above.
- Fragments with improved activity in modulating or inhibiting the differentiation and/or maturation of DCs may, of course, be rationally designed by the systematic mutation or fragmentation of the amino acid sequences of any one of SEQ ID NOs: 2, 4 or 6 or SEQ ID NOs: 24, 25, 26, 27, 28 or 29.
- fragments of the proteins of the invention or homologues thereof may be at least 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 or more amino acids in length. Fragments of the invention may comprise at least 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 or more consecutive amino acids from the amino acid sequence of any one of SEQ ID NOs: 2, 4 or 6 or homologues thereof.
- Fragments of the invention may comprise at least 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 or more consecutive amino acids from the amino acid sequence of any one of i) SEQ ID NOs: 2, 25 or 28, ii) SEQ ID NOs: 4, 26 or 29 or iii) SEQ ID NOs: 6, 24 or 27, or homologues thereof.
- Protein fragments of the invention may retain one or more of the conserved motifs and features of the DC modulatory proteins of SEQ ID NOs: 2, 4, 6, 24, 25, 26, 27, 28 and 29. In one embodiment, protein fragments of the invention may retain one or more of the conserved motifs and features of the DC modulatory proteins of SEQ ID NOs: 2, 4 and 6. As described below, these include a conserved glycosylation site containing sequence, cysteine distribution pattern, CXXW motif, lipid binding ability, and receptor binding ability.
- the proteins of the invention may be glycosylated at one or more positions.
- the protein may be glycosylated at one, two, three or more positions.
- the proteins of the invention are preferably N-glycosylated, (i.e. a polysaccharide is attached to an asparagine amino acid residue) although the protein may also be O-glycosylated (i.e. N-acetyl-galactosamine is attached to a serine or threonine residue) at one or more positions.
- the carbohydrate moiety may include one or more mannose or fucose or galactose units.
- DC modulatory proteins of the inventions have a consensus sequence around the glycosylation site.
- This consensus sequence has the amino acid residue to be glycosylated at a conserved position.
- the amino acid residue to be glycosylated is an asparagine residue (in the case of N- glycosylation) or a serine or threonine residue (in the case of O-glycosylation).
- the proteins of the invention have the amino acid residue asparagine at amino acid position 1 15 of RaA (SEQ ID NO: 2), 113 of RaB (SEQ ID NO: 4) and 116 of Rsl (SEQ ID NO: 6).
- the proteins of the invention have the amino acid residue asparagine at amino acid position 154 of full length RaA protein (SEQ ID NO: 25), 153 of full length RaB protein (SEQ ID NO:26) or 155 of full length Rsl protein (SEQ ID NO:24). These positions correspond to residue 155 of the amino acid sequence of Japanin (SEQ ID NO: 8). Therefore, in one embodiment the proteins of the invention have a conserved asparagine residue at a residue corresponding to any one of amino acid positions 1 10— 120 of the sequences of any one of SEQ ID NOs: 2, 4 or 6.
- proteins of the invention have a conserved asparagine residue at a residue corresponding to amino acid position 115 of RaA (SEQ ID NO: 2), 1 13 of RaB (SEQ ID NO: 4) or 1 16 of Rsl (SEQ ID NO: 6).
- proteins of the invention have a conserved asparagine residue at the amino acid position which corresponds to amino acid position 155 of the amino acid sequence of Japanin (SEQ ID NO: 8).
- the protein of the invention or homologue or fragment thereof comprises the glycosylation site containing sequence N-Z-(S/T)-(X) 3 . 5 -C, wherein X is any amino acid and Z is any amino acid except proline
- the protein of the invention or homologue or fragment thereof comprises the glycosylation site containing sequence (X) 12-16 -N-Z-(S/T)-(X) 3-5 -C, wherein X is any amino acid and Z is any amino acid except proline.
- the protein of the invention or homologue or fragment thereof comprises the glycosylation site containing sequence W-(X) 1 2-i 6 -N-Z-(S/T)-(X) 3-5 -C, wherein X is any amino acid and Z is any amino acid except proline
- the protein of the invention or homologue or fragment thereof comprises the glycosylation site containing sequence C-(X) 2 -W-(X)] 2 . ]6 -N-Z-(S/T)-(X) 3 . 5 -C, wherein X is any amino acid and Z is any amino acid except proline.
- the protein of the invention or homologue or fragment thereof comprises the glycosylation site containing sequence C-(X) 2 -W-(X)i 2 .i 6 -N-Z-(S/T)- (F/Y)-(X) 2- 4-C, wherein X is any amino acid and Z is any amino acid except proline.
- the protein of the invention or homologue or fragment thereof comprises the glycosylation site containing sequence C-(X) 2 -W-(X) 7- u-(I/L)-P-(X) 3 -N- Z-(S/T)-(X)3-5-C, and wherein X is any amino acid and Z is any amino acid except proline.
- the protein of the invention or homologue or fragment thereof comprises the glycosylation site containing sequence C-(X) 2 -W-(X) 7-U -(I/L)-P-(X) 3 -N- Z-(S/T)-(F/Y)-(X) 2 ⁇ -C, wherein X is any amino acid and Z is any amino acid except proline.
- the protein of the invention or homologue or fragment thereof comprises the glycosylation site containing sequence C-(X) 2 -W-(X) 13 _] 5 -N-Z-(S/T)-(X)4- C, wherein X is any amino acid and Z is any amino acid except proline.
- Proteins of the invention may be glycosylated naturally. This may particularly be the case if the protein is produced naturally and isolated, or if the protein is produced recombinantly in a host cell which mirrors the glycosylation pattern of the organism in which the protein is naturally produced. Alternatively, it may be necessary to artificially glycosylate the protein of the invention.
- the present invention includes homologues and fragments of the amino acid sequences of SEQ ID NOs: 2, 4 and 6 or of SEQ ID NOs 24, 25, 26, 27, 28 or 29.
- Homologues or fragments of the invention may retain the glycosylation site containing sequence of the full length sequences of SEQ ID NOs: 2, 4, 6, 24, 25, 26, 27, 28 or 29.
- the homologues or fragments may retain the glycosylation site containing sequence of the full length sequences of SEQ ID NOs: 2, 4 and 6.
- the homologues and fragments may retain one or more of the glycosylation site containing sequences described above.
- the sequence homology between the proteins of the inventions and the previously identified DC modulatory protein Japanin indicates that, like Japanin, the proteins of the invention are lipocalins, or lipocalin-like molecules.
- the lipocalins are a family of proteins which share a similar structural fold.
- the characteristic lipocalin fold is an eight-stranded anti-parallel beta-barrel, which forms an internal cavity that in most cases acts as a ligand binding site.
- the lipocalins in general, contain cysteine residues at spaced locations. At least some of the cysteine residues, in general, form internal disulphide bonds, which may stabilise the lipocalin fold.
- the inventors have discovered that the DC modulatory proteins of the invention possess a conserved cysteine distribution pattern.
- This cysteine distribution pattern is believed to be required in order to form the specific lipocalin fold of the DC modulatory proteins of the present invention, and is configured to allow the binding of a lipid molecule such as cholesterol to the proteins, as discussed in more detail below.
- the cysteine distribution pattern may also be required in order to stabilise the specific lipocalin fold.
- the proteins of the invention comprise the cysteine distribution pattern C-(X) 82- 92-C-(X)2 2-2 6-C-(X) 1 o-i2-C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern C-(X) 81- 9 1 -C-(X) 22- 26-C-(X) 1 o-i2-C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern C-(X)8 1- 92-C-(X) 2 2 -2 6-C-(X)io-i 2 -C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern C-(X)82-92-C-(X) 2 3-26-C-(X) 1 o-i2-C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern C-(X) 8 i-9i-C-(X)22-27-C-(X) 1 o-i2-C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern C-(X) 8 i-9 2 -C-(X) 2 3 -2 7-C-(X)io-i2-C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern C-(X) 8 2-92-C-(X)22-26-C-(X)n -1 2-C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern C-(X) 8 i-9 1 -C-(X) 2 2-26-C-(X) 1 o-i3-C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern C-(X)8i-92-C-(X)22-26-C-(X) 1 o-i 3 -C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern C-(X) 8 2-92-C-(X)23-26-C-(X)n-i2-C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern C-(X) 8 i-9i-C-(X)22-27-C-(X) 10-1 3-C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern C-(X) 8 i-92-C-(X)23-27-C-(X) 1 i -1 3-C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern C-(X) 82 -9i-C-(X)22-26-C-(X) 1 o-i2-C, wherein X is any amino acid. In another embodiment, the proteins of the invention comprise the cysteine distribution pattern C-(X)82-9i-C-(X)2-W-(X)]9 -2 3-C-(X)io-i 2 -C, wherein X is any amino acid.
- the proteins of the invention comprise the cysteine distribution pattern and glycosylation site containing sequence C-(X) 8 2-9i-C-(X)2-W-(X) 12-1 -N-Z- (S/T)-(X) 4 -C-(X)io-i2-C, wherein X is any amino acid and Z is any amino acid except proline.
- the cysteine distribution pattern of the identified proteins has the amino acid residue tryptophan at amino acid position 101 of RaA (SEQ ID NO: 2), 100 of RaB (SEQ ID NO: 4) and 102 of Rsl (SEQ ID NO: 6). These positions correspond to residue 141 of the amino acid sequence of Japanin (SEQ ID NO: 8). Therefore, in one embodiment the proteins of the invention have a conserved tryptophan residue at a residue corresponding to any one of amino acid positions 100 - 105 of the sequences of any one of SEQ ID NOs: 2, 4 and 6.
- proteins of the invention have a conserved tryptophan residue at a residue corresponding to amino acid position 101 of RaA (SEQ ID NO: 2), 100 of RaB (SEQ ID NO: 4) or 102 of Rsl (SEQ ID NO: 6).
- cysteine distribution pattern of the identified proteins has the amino acid residue tryptophan at amino acid position 140 of full length RaA protein (SEQ ID NO: 25), position 139 of full length RaB protein (SEQ ID NO: 26) and position 141 of full length Rsl protein (SEQ ID NO: 24). These positions correspond to residue 141 of the amino acid sequence of Japanin (SEQ ID NO: 8). Therefore, in one embodiment the proteins of the invention have a conserved tryptophan residue at a residue corresponding to any one of amino acid positions 137 - 143 of the sequences of any one of SEQ ID NOs: 24, 25 and 26.
- proteins of the invention have a conserved tryptophan residue at a residue corresponding to amino acid position 140 of full length RaA protein (SEQ ID NO: 25), position 139 of full length RaB protein (SEQ ID NO: 26) and position 141 of full length Rsl protein (SEQ ID NO: 24).
- proteins of the invention have a conserved tryptophan residue at the amino acid position which corresponds to amino acid position 141 of the amino acid sequence of Japanin (SEQ ID NO: 8).
- the present invention includes homologues and fragments of the amino acid sequences of SEQ ID NOs: 2, 4 and 6 or of SEQ ID NOs 24, 25, 26, 27, 28 or 29.
- the homologues or fragments may the retain cysteine distribution pattern of the proteins of the invention, and may retain the consensus sequence described above.
- lipid is intended to encompass any hydrophobic or amphiphilic molecule which is soluble in organic solvents but insoluble in water. This includes fats, oils, triacylglycerols, glycolipids, phospholipids and steroids, fatty acyls, fatty acids, glycerolipids, glycerophospholipids, sphingolipids, saccharolipids, polyketides, sterol lipids and prenol lipids.
- lipid-like molecule encompasses any molecule having similar or identical properties to a lipid.
- lipid-like molecule any lipid complexed to a non-lipid molecule. This includes glycolipids, phospolipids, phosphoglycolipids, labeled lipids and acetylated lipids.
- the protein of the invention may become bound to a lipid molecule during or immediately after its folding in the endoplasmatic reticulum or at a subsequent stage after its export from this location.
- the protein of the invention may become associated with the lipid during its production.
- the protein of the invention may automatically become associated with the lipid without any intervention being required.
- the lipid may be added to a composition comprising the protein of the invention in order to allow complex formation to occur between the lipid and the protein.
- the lipid may be added exogenously to a composition comprising the protein in order for complex formation to occur.
- the protein of the invention may be "associated” or “complexed” with the lipid. These terms are used interchangeably herein to relate to any sort of contact between the lipid and the protein of the invention.
- this interaction may be purely structural i.e. the lipid may fit into a binding pocket within the protein through a tessellating relationship.
- the lipid may physically interact with the protein through any attractive force.
- attractive forces may include electrostatic interactions, hydrophobic interactions, hydrophilic interactions, van der Waals forces, hydrogen bonds, and covalent interactions.
- the interaction between the lipid and the protein may be formed from a combination of a structural interaction and an attractive force.
- the protein of the invention may be associated with a lipid.
- the lipid may be a steroid or a sterol, for example cholesterol.
- the lipid may be a metabolite of cholesterol, such as vitamin D3 or dexamethasone.
- the invention thus provides a complex which comprises or consists of a protein of the invention and a lipid, for example cholesterol or a metabolite of cholesterol.
- the present invention includes homologues and fragments of the amino acid sequences of SEQ ID NOs: 2, 4 and 6 or of SEQ ID NOs 24, 25, 26, 27, 28 or 29.
- the homologues or fragments may retain the lipid binding properties of the full length proteins of SEQ ID NOs: 2, 4 and 6.
- the homologues and fragments may retain the ability to bind cholesterol or a metabolite of cholesterol such as vitamin D3 or dexamethasone.
- the invention also includes a complex which comprises or consists of a homologue or fragment of a protein of the invention and a lipid, for example cholesterol or a metabolite of cholesterol.
- the invention therefore includes a carrier protein which binds a lipid and targets a receptor on the surface of DCs.
- a carrier protein does not itself possess biological activity to modulate, and preferably inhibit, the maturation and differentiation of DCs.
- a carrier protein may be produced by engineering a modulatory protein of the invention to prevent its biological activity.
- the lipid carried by the carrier protein may confer a biological function by binding to a cellular receptor.
- the term "functional equivalent" as used above thus includes carrier proteins.
- CXXW motif The inventors have surprisingly discovered that all of the identified DC modulatory proteins share a CXXW motif, where X is any amino acid. The inventors have postulated that this motif is likely to be involved in the formation of the specific lipocalin structure of the DC modulatory proteins.
- the CXXW motif may be involved in the binding of a lipid, for example cholesterol within the barrel-like structure of the lipocalin. The lipid may become bound to one of the residues of this motif, or the motif may result in the formation of a binding pocket of suitable size to facilitate binding of a lipid within the barrel structure.
- the CXXW motif of the identified proteins is present at amino acid positions 98-101 of RaA (SEQ ID NO: 2), 97-100 of RaB (SEQ ID NO: 4) and 99-102 of Rsl (SEQ ID NO: 6). These positions correspond to residues 138-141 of the amino acid sequence of Japanin (SEQ ID NO: 8). Therefore, in one embodiment the proteins of the invention have a conserved CXXW motif at residues corresponding to any one of amino acid positions 95 - 105 of the sequences of any one of SEQ ID NOs: 2, 4 and 6.
- the proteins of the invention have a conserved CXXW motif at residues corresponding to amino acids 98-101 of RaA (SEQ ID NO: 2), 97-100 of RaB (SEQ ID NO: 4) or 99-102 of Rsl (SEQ ID NO: 6).
- the CXXW motif of the identified proteins is present at amino acid positions 137-140 of full length RaA protein (SEQ ID NO: 25), positions 136 - 139 of full length RaB protein (SEQ ID NO: 26) and positions 138-141 of full length Rsl protein (SEQ ID NO: 24). These positions correspond to residues 138-141 of the amino acid sequence of Japanin (SEQ ID NO: 8).
- the proteins of the invention have a conserved CXXW motif at residues corresponding to any one of amino acid positions 133-144 of the sequences of any one of SEQ ID NOs: 24, 25 and 26.
- the proteins of the invention have a conserved CXXW motif at residues corresponding to amino acids positions 137- 140 of full length RaA protein (SEQ ID NO: 25), positions 136 - 139 of full length RaB protein (SEQ ID NO: 26) and positions 138-141 of full length Rsl protein (SEQ ID NO: 24).
- the proteins of the invention have a conserved CXXW motif at the amino acid position which corresponds to amino acids 138-141 of the amino acid sequence of Japanin (SEQ ID NO: 8).
- the DC modulatory protein of the invention may comprise the motif CXXW, wherein X is any amino acid. In another embodiment, the DC modulatory protein of the invention may comprise the motif CXLW, wherein X is any amino acid.
- the DC modulatory protein of the invention may comprise the motif CSLW or CELW.
- the CXXW motif may be followed by a valine residue and the proteins of the invention may therefore include the motif CXXWV.
- the motif may comprise the residues CXLWV, CSLWV or CELWV.
- the motif forms part of the barrel-like structure of the lipocalin, and that the small size of the serine residue in the CSLW motif allows a lipid molecule, such as cholesterol to enter the barrel and become bound within the barrel structure. Therefore, in a preferred embodiment the proteins of the invention comprise a CSLW motif.
- the present invention includes homologues and fragments of the amino acid sequences of SEQ ID NOs: 2, 4 and 6 or of SEQ ID NOs 24, 25, 26, 27, 28 or 29.
- the homologues or fragments may retain the CXXW motif.
- the homologues and fragments may retain the CXLW motif or the CELW or CSLW motif.
- the DC modulatory proteins of the invention are thought to bind to a Ca dependent receptor.
- This receptor may be a lectin receptor and in particular may be a C-type lectin cell surface receptor. This suggests that these proteins function to modulate, and preferably inhibit, the differentiation and/or maturation of dendritic cells by binding to a receptor on the surface of the target cell and triggering an internal cell signalling pathway which causes the inhibition.
- the proteins of the invention may modulate directly or indirectly a target cell such as a DC.
- the protein may bind to a receptor on the outer surface of a target cell, for example a DC.
- the protein may bind to a divalent cation-dependent receptor.
- the protein may bind to a Ca dependent receptor.
- the protein may bind to a lectin receptor and in particular may bind to a C-type lectin receptor.
- the protein may bind to a receptor and mimic a natural ligand for the receptor. It will be apparent to a person skilled in the art that any part of the protein may bind to the receptor.
- the protein may be glycosylated and/or bound to a lipid molecule, it may be the carbohydrate moiety or the associated lipid which binds to the receptor on the target cell.
- the protein may bind to a receptor that is internal to a target cell.
- the protein may bind to an internal receptor on the surface of a lysosome or other cell organelle.
- the protein of the invention may indirectly modulate a DC cell by binding to one or more intermediate proteins (e.g. a plasma protein) in which the intermediate protein directly or indirectly modulates a DC.
- the intermediate protein may directly bind to a DC receptor.
- a complex comprising or consisting of a protein of the invention and the receptor.
- the complex may comprise or consist of a protein of the invention, the receptor, for example a divalent cation-dependent receptor such as a C-type lectin receptor and a lipid, for example cholesterol or a metabolite of cholesterol.
- the invention also provides an antibody which binds the proteins and fragments and homologues thereof of the present invention.
- the antibody may be used as a reagent for the detection of proteins of the invention. It may also be an antibody that neutralises the activity of proteins of the invention in modulating or inhibiting the DC differentiation and/or maturation and is thus useful for therapeutic purposes, as described below. Included within this aspect of the invention are antibodies which bind to any of the homologues and protein fragments included within the scope of the invention, as described above.
- the invention also includes antibodies which bind to a carbohydrate moiety of the protein of the invention.
- the invention includes antibodies which bind to one or more of the carbohydrate moieties naturally attached to the proteins of the invention and homologues and fragments thereof.
- the invention includes antibodies that mimic the ability of proteins of the invention to modulate, and preferably inhibit, the differentiation and/or maturation of DCs.
- Anticalins are also included within the scope of the invention. These are molecules which are engineered from lipocalins to recognise and bind specific protein epitopes. In certain embodiments anticalins may take the form of peptides, glycopeptides or glycolipids. Herein, anticalins are included within the scope of the term "antibodies”. Anticalins are non-immunoglobulin-derived molecules which nevertheless recognise protein epitopes in a manner similar to antibodies. If polyclonal antibodies are desired, a selected mammal, such as a mouse, rabbit, pig, goat or horse, may be immunised with a protein of the invention or a homologue or fragment thereof. If desired, the protein can be conjugated to a carrier protein.
- carrier proteins include bovine serum albumin, thyroglobulin and keyhole limpet haemocyanin.
- the coupled protein is then used to immunise the animal. Serum from the immunised animal is collected and treated according to known procedures, for example by immunoaffinity chromatography.
- Monoclonal antibodies to the proteins of the invention and homologues and fragments thereof can also be readily produced by one skilled in the art.
- the general methodology for making monoclonal antibodies using hybridoma technology is well known (see, for example, Kohler, G. and Milstein, C, Nature 256: 495-497 (1975); Kozbor et al, Immunology Today 4: 72 (1983); Cole et al , 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985).
- antibody includes full length antibodies and fragments of antibodies, such as Fab, F(ab') 2 and Fv fragments, which also bind specifically to a protein of the invention or a homologue or fragment thereof.
- antibody further includes chimeric and humanised antibody molecules having specificity for the proteins of the invention and homologues and fragments thereof. Chimeric antibodies are antibodies in which non-human variable regions are joined or fused to human constant regions (see, for example, Liu et al, Proc. Natl. Acad. Sci. USA, 84, 3439 (1987)).
- humanised antibody refers to antibody molecules in which the CDR amino acids and selected other amino acids in the variable domains of the heavy and/or light chains of a non-human donor antibody have been substituted in place of the equivalent amino acids in a human antibody.
- the humanised antibody thus closely resembles a human antibody but has the binding ability of the donor antibody (see Jones et al, Nature, 321, 522 (1986); Verhoeyen et al, Science, 239, 1534 (1988); Kabat et al , J. Immunol., 147, 1709 (1991); Queen et al, Proc. Natl Acad. Sci. USA, 86, 10029 (1989); Gorman et al , Proc. Natl Acad. Sci. USA, 88, 34181 (1991); and Hodgson et al, Bio/Technology, 9, 421 (1991)).
- Such humanised antibodies are also included within the scope of the invention.
- antibody also includes a "plastic” antibody (molecularly imprinted polymer (MIP)).
- MIP molecularly imprinted polymer
- a label group may be an enzyme, a radiolabel, a compound such as bio tin, or a fluorochrome.
- labelled antibodies are also within the scope of the invention.
- the invention also includes a fusion protein comprising a protein of the invention or a homologue or fragment thereof that is genetically fused or chemically linked to one or more peptides, polypeptides or other molecules.
- the purpose of the additional peptide or polypeptide or molecule may be to aid detection, expression, separation or purification of the protein or it may be to confer additional properties to the protein as desired.
- potential fusion partners include beta-galactosidase, glutathione-S- transferase, luciferase, a polyhistidine tag, a T7 polymerase fragment and a secretion signal peptide.
- the fusion partner may also extend the life of the molecules in vivo, e.g. an Fc fragment.
- fusion partners include potential biopharmaceuticals, such as proteins or other molecules that are being developed for use as drugs to treat specific diseases.
- Further potential fusion partners include antigens that will target the protein of the invention to cells within the immune system, such as DCs.
- fusion partners may include a self or foreign antigen or an allergen which may be fused to the protein to deliver it to the DCs in vivo.
- Further fusion partners may include molecules that bind to a different cell surface component of the DC to facility delivery to the DC. Examples of such antigens are discussed in more detail below in relation to methods of treatment. In some cases, multiple fusion partners may be included.
- the invention also includes a nucleic acid molecule comprising a nucleic acid sequence encoding a protein of the invention. Included within the term "nucleic acid molecule” are DNA molecules, RNA molecules and mixed DNA-RNA molecules. Further included within this definition are genomic DNA, cDNA molecules, mRNA molecules and RNA and DNA molecules containing modified bases. As will be apparent to a person skilled in the art, the degeneracy of the genetic code provides that there will be a number of different nucleic acid sequences which are capable of encoding the defined protein sequence of a protein of the invention or a homologue or fragment thereof. The invention also includes a nucleic acid molecule encoding a fusion protein, such as the fusion proteins described above.
- the nucleic acid molecule comprising a nucleic acid sequence encoding a protein of the invention may comprise or consist of the nucleotide sequence of any one of SEQ ID NOs: 1, 3, 5 or a degenerate sequence thereof.
- the nucleic acid molecule comprising a nucleic acid sequence encoding a protein of the invention may comprise or consist of the nucleotide sequence of any one of SEQ ID NOs: 41, 42 or 43 or a degenerate sequence thereof.
- the invention also provides an antisense nucleic acid molecule which hybridises under high stringency hybridisation conditions to a nucleic acid molecule comprising a nucleic acid sequence encoding a protein of the invention, or a homologue or fragment thereof, as described above.
- High stringency hybridisation conditions include overnight incubation at 42°C in a solution comprising 50% formamide, 5XSSC (150mM NaCl, 15mM trisodium citrate), 50mM sodium phosphate (pH7.6), 5xDenhardts solution, 10% dextran sulphate, and 20 microgram/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1X SSC at approximately 65°C.
- Antisense nucleic acid molecules include antisense DNA oligonucleotides, and RNA oligonucleotides including siRNA.
- the invention also includes a vector containing a nucleic acid molecule comprising a nucleic acid sequence encoding a protein of the invention or a homologue or fragment thereof or an antisense nucleic acid molecule which hybridises under high stringency hybridisation conditions to said nucleic acid molecule.
- Said vectors include cloning and expression vectors.
- Such expression vectors may incorporate the appropriate transcriptional and translational control sequences, for example enhancer elements, promoter-operator regions, termination stop sequences, mRNA stability sequences, start and stop codons or ribosomal binding sites, linked in frame with the nucleic acid molecules of the invention. These control sequences are provided by way of example only, and are not intended to be limited.
- nucleic acid sequences encoding secretion, signalling and processing sequences may include nucleic acid sequences encoding secretion, signalling and processing sequences.
- Vectors according to the invention may include plasmids and viruses (including both bacteriophage and eukaryotic viruses), as well as other linear or circular DNA carriers, such as those employing transposable elements or homologous recombination technology.
- Particularly suitable viral vectors include baculovirus-, lentivirus-, adenovirus- and vaccinia virus- based vectors.
- the invention also includes a host cell containing a vector, a nucleic acid molecule or an antisense nucleic acid encoding a protein of the invention or a homologue or fragment thereof.
- a host cell may be a prokaryotic host cell.
- the prokaryotic host cell may be an E. coli host cell.
- the host cell may be a eukaryotic host cell.
- the host cell may be a eukaryotic yeast cell.
- the host cell may be a mammalian host cell.
- the host cell may be an insect cell, and within this embodiment the expression system may be the baculovirus expression system.
- transformation or transfection techniques are well described in the literature (Sambrook et al, 1989; Ausubel et al, 1991 ; Spector, Goldman & Leinwald, 1998).
- expression systems may either be transient (e.g. episomal) or permanent (chromosomal integration) according to the needs of the system.
- a method of preparing a protein of the invention, or a homologue or fragment thereof comprising: i) culturing a host cell containing a vector comprising a nucleic acid sequence which encodes a protein of the invention or a homologue or fragment thereof under conditions whereby said protein is expressed; and
- the conditions required for protein expression will vary depending upon the host cell system, the vector and the subsequent method of protein recovery.
- One example of a particular process for production and recovery of the proteins of the invention includes infecting Sf9 insect cells with a recombinant baculovirus encoding a protein of the invention and precipitating the resulting protein from the culture supernatant by the addition either of polyethylene glycol (PEG) or ammonium sulphate. Variation in such conditions will be apparent to a person skilled in the art.
- the proteins, nucleic acids, antisense nucleic acids, vectors, host cells and antibodies of the present invention are intended to be used as therapeutics.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a DC modulatory protein which modulates, and preferably inhibits, the differentiation and/or maturation of DCs, or a functional equivalent or fragment thereof, a nucleic acid encoding such a protein, homologue or fragment, a vector containing said nucleic acid, a host cell containing said vector or an antibody which binds to said protein, homologue or fragment and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier includes genes, polypeptides, antibodies, liposomes, polysaccharides, polylactic acids, polyglycolic acids and inactive virus particles or indeed any other agent provided that the excipient does not itself induce toxicity effects or cause the production of antibodies that are harmful to the individual receiving the pharmaceutical composition.
- Pharmaceutically acceptable carriers may additionally contain liquids such as water, saline, glycerol, ethanol or auxiliary substances such as wetting or emulsifying agents, pH buffering substances and the like. Excipients may enable the pharmaceutical compositions to be formulated into tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, or suspensions to aid intake by the patient.
- a thorough discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).
- the pharmaceutical composition may include one or more lipid molecules which interact with the protein.
- this lipid molecule may be a steroid or a sterol, for example cholesterol or a metabolite of cholesterol, such as vitamin D3 or dexamethasone.
- the pharmaceutical composition may include a complex which comprises or consists of a protein of the invention and a lipid, for example cholesterol or a metabolite of cholesterol such as vitamin D3 or dexamethasone.
- the pharmaceutical composition may include a complex which comprises or consists of a protein of the invention, a lipid, for example cholesterol or a metabolite of cholesterol such as vitamin D3 or dexamethasone, and a receptor, for example a divalent cation- dependent receptor such as a C-type lectin receptor.
- a complex which comprises or consists of a protein of the invention, a lipid, for example cholesterol or a metabolite of cholesterol such as vitamin D3 or dexamethasone, and a receptor, for example a divalent cation- dependent receptor such as a C-type lectin receptor.
- the pharmaceutical composition may also include one or more additional therapeutic agents. Included within this aspect of the invention are any additional therapeutic agents which the skilled person might consider would be advantageous for co-administration with the proteins of the invention.
- said additional therapeutic agent may comprise an anti-inflammatory agent, an immunomodulatory agent, an immunosuppressant, a cytokine, a cytokine mimetic or a cytokine binding protein.
- the one or more additional therapeutic agents may include an anti-inflammatory agent.
- the present invention provides a protein, which modulates, and preferably inhibits, the differentiation and/or maturation of mammalian DCs, a nucleic acid encoding such a protein, an antisense nucleic acid, a vector containing said nucleic acid or antisense nucleic acid, a host cell containing said vector, an antibody which binds to said protein or a pharmaceutical composition comprising said protein, nucleic acid, vector, host cell or antibody for use in therapy.
- the term "therapy” includes use of the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions described herein for the benefit of a human or animal patient. Specifically this term includes therapeutic treatment, prophylactic treatment, diagnosis, and vaccination. This list is provided by way of illustration only, and is not intended to be limiting.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the present invention may be used for the treatment of any animal.
- this animal may be a fish.
- this animal may be a mammal.
- this mammal may be a cow, pig, sheep, cat, dog, bird such as a chicken, or rabbit.
- the mammal may be a human.
- the animal may be a reptile.
- a DC modulatory protein in another embodiment, there is provided the use of a DC modulatory protein, a nucleic acid encoding such a protein, an antisense nucleic acid capable of binding to the nucleic acid encoding such a protein, a vector containing said nucleic acid or antisense nucleic acid, a host cell containing said vector, an antibody which binds to said protein or nucleic acid molecule or a pharmaceutical composition comprising said protein, nucleic acid, vector, host cell or antibody in the manufacture of a medicament for treating diseases associated with DC activity.
- the invention also provides a method of treating an animal suffering from a disease associated with DC activity comprising administering to said animal a DC modulatory protein, a nucleic acid encoding such a protein, an antisense nucleic acid capable of binding to the nucleic acid encoding such a protein, a vector containing said nucleic acid or antisense nucleic acid, a host cell containing said vector, an antibody which binds to said protein or a pharmaceutical composition comprising said protein, nucleic acid, vector, host cell or antibody in a therapeutically effective amount.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the present invention may be administered to a patient using any one or more of a number of modes of administration.
- modes of administration are well known in the art and may include parenteral injection ⁇ e.g. intravenously, subcutaneously, intraperitoneally, intramuscularly, or to the interstitial space of a tissue), or by rectal, oral, vaginal, topical, transdermal, intradermal, intrathecal, intranasal, ocular, aural, pulmonary or other mucosal administration.
- Nanopatches may be used for transdermal administration of the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the present invention.
- Gene guns may also be used to administer the nucleic acids, vectors, or pharmaceutical compositions of the invention. The precise mode of administration will depend on the disease or condition to be treated.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention may be used in the treatment or prevention of autoimmune disorders, allergies or other hypersensitivity disorders, transfusion reactions, transplant reactions including transplant reactions such as transplant rejection and graft-versus-host disease, and acute and chronic inflammatory diseases.
- the autoimmune disorders include but are not limited to achlorhydra autoimmune chronic active hepatitis, Addison's disease, alopecia areata, amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease), ankylosing spondylitis, anti-GBM nephritis or anti-TBM nephritis, antiphospholipid syndrome, aplastic anemia, arthritis, asthma, atopic allergy, atopic dermatitis, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune lymphoproliferative syndrome (ALPS), autoimmune thrombocytopenic purpura (ATP), Balo disease, Behcet's disease, Berger's disease (IgA Nephropathy), bullous pemphigoid, cardiomyopathy, celiac disease, celiac sprue dermatitis, chronic fatigue immune deficiency syndrome (CFIDS), chronic fatigue
- the allergy or other immune-related sensitivity may be any known hypersensitivity disease including type I, type II, type III, or type IV according to the Gell-Coombs classification, and the less commonly defined type V hypersensitivity disorders.
- Such disorders include but are not limited to atopy, asthma, ertyhroblastosis fetalis, Goodpasture's syndrome, autoimmune hemolytic anemia, serum sickness, Arthus reaction, systemic lupus erythematosus, contact dermatitis, tuberculin skin test, chronic transplant rejection, Graves disease, myasthenia gravis, systemic anaphylaxis, local anaphylaxis, allergic rhinitis, conjunctivitis, gastroenteritis, eczema, blood transfusion reactions, haemolytic disease of the newborn, rheumatoid arthritis, glomerulonephritis, contact dermatitis, atopic dermatitis, tubercular lesions, drug-induced hemolytic anemia,
- the allergy or hypersensitivity disorder may be associated with infectious diseases including but not limited to tuberculosis, leprosy, blastomycosis, histoplasmosis, toxoplasmosis, leishmaniasis or other infections.
- Allergies that may be treated include but are not limited to allergic reactions to pollens (e.g. birch tree, ragweed, oil seed rape), food (e.g. nuts, eggs or seafood), drugs (e.g. penicillin or salicylates), insect products (e.g. bee or wasp venom or house dust mites) or animal hair, and man-made products such as latex. Allergies that may be treated may also include allergic reactions to arthropod products.
- inflammatory diseases include atherosclerosis or other cardiovascular disease, Alzheimer's disease, vasculisitis, myositis, encephalitis, reperfusion injury, type 2 diabetes, fatty liver disease, and wound healing, including the inflammatory phase, the process of angiogenesis, fibroplasmia and epithelialisation, and the remodeling phase.
- Further inflammatory diseases include cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention may also be used in the treatment or prevention of nasal polyposis, pre-eclampsia pregnancy induced hypertension, Eales' disease or acute pancreatitis.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention may be used in the treatment or prevention of harmful conditions resulting from bodily fluids or tissues coming into contact with artificial or non-mammalian materials during the course of therapeutic or diagnostic procedures.
- Such procedures may be temporary or permanent and include but not be limited to the use of extracorporeal circuits including renal or hepatic haemodialysis, peritoneal dialysis, cardiopulmonary bypass and haemofiltration, indwelling catheters whether placed in blood vessels, the urinary bladder, the intrathecal space or any other hollow viscus, implanted prostheses including artificial joints, heart valves, endovascular stents, CSF shunts, vascular prostheses and coronary angioplasty catheters.
- extracorporeal circuits including renal or hepatic haemodialysis, peritoneal dialysis, cardiopulmonary bypass and haemofiltration, indwelling catheters whether placed in blood vessels, the urinary bladder, the intrathecal space or any other hollow viscus, implanted prostheses including artificial joints, heart valves, endovascular stents, CSF shunts, vascular prostheses and coronary angioplasty catheters.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention are likely to have an immunosuppressant effect that may be useful in preventing transplantation reactions such as transplant rejection.
- the transplants may be autografts between the same individual, isografts between genetically matched individuals, allografts between different members of the same species or xenografts between different species.
- the proteins of the invention may be useful in preventing rejection of a range of transplants including, but not limited to heart, lung, heart and lung, kidney, liver, pancreas, intestine, hand, cornea, skin graft including face replant and face transplants, islets of Langerhans, bone marrow transplants, blood transfusion, blood vessels, heart valves, bone and skin.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention may be used to prevent graft- versus host disease following bone marrow transplantation.
- the proteins of the invention may be involved in inhibiting signalling pathways involved in cancer.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention may be used in the treatment of cancer.
- the invention also provides a method of treating an animal suffering from cancer comprising administering to said animal a protein, nucleic acid, vector, antibody, or pharmaceutical composition of the invention, as described above in a therapeutically effective amount. Such treatment may involve the repolarisation or modulation of the immune response in cancer.
- the cancer may be a haematological cancer such as lymphoma or leukaemia or multiple myeloma.
- Leukemias that may be treated according to the invention include acute lymphoblastic leukaemia (ALL), acute myelogenous leukaemia (AML), chronic myelogenous leukaemia (CML), chronic lymphocytic leukaemia (CLL) and hairy cell leukaemia.
- Lymphomas that may be treated according to the invention include Hodgkin's disease and non-Hodgkin's lymphoma.
- MDS myelodysplastic syndrome
- ALL myeloproliferative disease including polycythemia vera, essential thrombocytosis or myelofibrosis, and amyloid due to light-chain disease.
- the cancer may be a carcinoma, a sarcoma, or a blastoma.
- the invention contemplates the treatment of cancers of any organ including but not limited to cancers of the breast, lung, ovaries, pancreas, testes, skin, colon, brain, liver or cervix, as well as melanoma.
- a cancer that may be treated or prevented is histiocytoma and in particular canine cutaneous histiocytoma.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention may be used in the treatment of infectious disease.
- treatment may involve the repolarisation or modulation of the immune response to infections by pathogens such as viruses, bacteria and protozoa, e.g. the causative agents of HIV, TB and malaria, as well as other parasites.
- Haematophagous arthropods such as ticks are sources of infectious disease agents such as tick-bome encephalitis virus, Crimean-Congo haemorrhagic fever virus, Washington sheep virus, Borrelia burgdorferi (the agent of Lyme's disease), and Theileria parva (the agent of East Coast fever). It is postulated that the proteins of the invention may act to promote transmission of tick-borne diseases. The proteins of the invention and homologues and fragments thereof may therefore be useful in the vaccination of animals to induce an immune response to treat or prevent tick-borne diseases.
- a method of preventing transmission of an arthropod-borne infectious disease or treating an arthropod-borne infectious disease comprising administering to an animal a protein, nucleic acid molecule, vector, host cell, antibody or pharmaceutical composition of the invention.
- the invention also provides a protein, nucleic acid molecule, vector, host cell, antibody or pharmaceutical composition of the invention for use in preventing transmission of an arthropod-borne infectious disease or treating an arthropod-borne infectious disease.
- the arthropod may be a haematophagous arthropod.
- the arthropod-borne disease may be Lyme's disease, tick- borne encephalitis, Crimean-Congo haemorrhagic fever, Kenya sheep virus or East coast fever.
- the proteins of the invention and homologues and fragments thereof may also be useful as vaccines against the haematophagous arthropods themselves, as well as the diseases carried by them.
- the invention therefore further provides a method of vaccinating an animal against a haematophagous arthropod which may be a tick, comprising administering a protein, nucleic acid molecule, vector, host cell, antibody or pharmaceutical composition of the invention to said animal.
- the invention also provides a protein, nucleic acid molecule, vector, host cell, antibody or pharmaceutical composition of the invention for use in vaccinating an animal against a haematophagous arthropod which may be a tick.
- proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention in combination with one or more additional therapeutic agents such as an antiinflammatory agent, an immunomodulatory agent, an immunosuppressant, a cytokine, a cytokine mimetic or a cytokine binding protein, or another biopharmaceutical developed for the treatment of any of the disorders mentioned above.
- additional therapeutic agents such as an antiinflammatory agent, an immunomodulatory agent, an immunosuppressant, a cytokine, a cytokine mimetic or a cytokine binding protein, or another biopharmaceutical developed for the treatment of any of the disorders mentioned above.
- proteins, nucleic acids, vectors, host cells or antibodies of the invention may be administered to the patient in combination with a disease-associated element to aid targeting of the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the present invention to the appropriate DCs.
- a disease associated element may not be necessary.
- disease-associated element is intended to encompass any component which is associated with the disease in a patient.
- the disease may include autoimmune disorders, allergies and other hypersensitivity reactions, transplant reactions such as transplant rejection and graft-versus-host disease, infectious diseases including those transmitted by ticks, cancers including haematological malignancies, and acute and chronic inflammatory diseases, as described above.
- the "disease associated element” may thus include: i) components associated with infectious agents, such as viruses, microbes, parasites and microbial toxins; ii) allergens that are non-self molecules associated with allergy; iii) non-self components associated with hypersensitivity reactions other than allergy; iv) self-components associated with autoimmune diseases; v) transplantation antigens from genetically-different members of the same species (alloantigens) or from different species (xenoantigens); and vi) tumour-associated antigens and tumour-specific antigens.
- disease associated element also encompasses fragments and derivatives of these disease-associated elements.
- Such derivatives may includes detoxified agents, synthetic mimotopes and antigens comprising substitutions, additions or deletions in their structure, which are still capable of acting to direct the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention to the appropriate DCs.
- Providing the animal with a disease-associated element will improve the specificity of the modulation or inhibition of DC differentiation and maturation associated with the disease. Targeting specific DCs in this manner is advantageous as it avoids the need to inhibit the overall immune response, and may therefore result in a reduced profile of side effects.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention may be administered separately from the disease associated element.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention and the disease associated element may be administered sequentially.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention may be administered before the disease associated element.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention may be administered after the disease associated element.
- the proteins, nucleic acids, vectors, host cells, antibodies or pharmaceutical compositions of the invention and the disease associated element may be administered simultaneously.
- the proteins, or antibodies of the invention may be bound to the disease associated element, for example in the form of a fusion protein.
- the invention therefore also provides, a fusion protein comprising a protein of the invention or a homologue or fragment thereof, and a disease associated element.
- a nucleic acid encoding such a fusion protein is also provided.
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a protein, nucleic acid, vector, host cell, antibody or pharmaceutical composition of the invention, a disease associated element and a pharmaceutically acceptable carrier.
- the methods describe above involve the administration of the proteins of the invention to an animal in order to modulate, and preferably inhibit, the differentiation and/or maturation of DCs in the animal in vivo.
- the proteins may be administered alone or in combination with additional agents, including disease associated elements that will target the protein of the invention to DCs.
- An alternative approach to the treatment of the diseases described above is to use the proteins of the invention for targeted therapy ex vivo.
- This approach involves delivering a protein of the invention to DCs in vitro to modulate the DCs and delivering the modulated DCs to the animal in need of treatment.
- the invention provides a method of modulating a DC, said method comprising contacting a DC with a protein of the invention, or a homologue or fragment thereof.
- a modulated DC produced using this method is also provided.
- the invention also provides a method of treating or preventing a disorder associated with DCs in an animal in need thereof wherein the method comprises administering the modulated DC produced by the method described above to an animal.
- the DCs may be isolated directly from the animal in need of treatment.
- DC precursors such as monocytes of bone marrow progenitors may be isolated from the animal in need of treatment and used to generate modulated DCs.
- the DC or DC precursors may be autologous or allogeneic with respect to the animal into which the modulated DCs are to be introduced following treatment of the DCs with a protein of the invention.
- the disorders associated with DCs may be any of the diseases discussed above including autoimmune disorders, allergies and other hypersensitivity reactions, transplant reactions such as transplant rejection and graft-versus-host disease, infectious diseases including those transmitted by ticks, cancers including haematological malignancies, and acute and chronic inflammatory diseases It is contemplated that this method may be used to generate modulated DCs from a transplant donor to administer to the intended recipient of a transplant prior to transplantation with the aim or inducing unresponsiveness to the graft and thus reducing the need for immunosuppressants to be given.
- the DCs may also be contacted with a disease associated element, as described above, in order to target the protein of the invention or the homologue or fragment thereof to the appropriate DCs.
- the modulated DCs may be administered to the animal in combination with a disease-associated element, such as those as described above.
- the identification of the cognate receptor of the proteins of the invention allows the receptor to be used in screening methods to identify potential agonists and antagonists of proteins of the invention in order to identify any compounds which are potentially of therapeutic or other use.
- Potential agonist or antagonist compounds may be isolated from, for example, cells, cell-free preparations, chemical libraries or natural product mixtures.
- screening techniques see Coligan et al., Current Protocols in Immunology 1(2): Chapter 5 (1991).
- Compounds that are most likely to be good antagonists are molecules that bind to the protein of the invention's cognate receptor without inducing the biological effects induced by the proteins of the invention, and thus competitively inhibit the function of the proteins of the invention.
- the cognate receptor of the proteins of the invention is thought to be a divalent cation-dependent receptor which is a C-type lectin receptor which, upon binding of the proteins of the invention, induces an intracellular signalling pathway leading to inhibition of differentiation and maturation of DCs.
- Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to the receptor without activating a signalling pathway, or by activating a negative signalling pathway.
- suitable potential antagonists include carbohydrate moieties and engineered molecules corresponding to proteins of the invention which have been engineered to reduce their function whilst retaining their binding affinity for the receptor.
- potential antagonists include small synthetic molecules that bind to the receptor without activating a signalling pathway or by activating a negative signalling pathway.
- suitable compounds include antibodies to the proteins of the invention and antibodies to the carbohydrate moiety associated with the proteins of the invention, and anticalins which can be engineered for target specificity.
- Compounds most likely to function as good agonists are compounds which bind to the cognate receptor of the proteins of the invention and induce the same intracellular signalling pathway as the proteins of the invention, thereby functioning to modulate, and preferably inhibit, the differentiation and maturation of DCs in a similar way to the proteins of the invention.
- suitable potential agonists include proteins of the invention which have been engineered to increase their ability to activate the receptor and/or their binding affinity for the receptor.
- suitable potential agonists include small organic molecules, synthetic molecules, peptides, polypeptides fusion proteins, antibodies or antibody fragments.
- the cognate receptor for use in such a screening technique may be free in solution, affixed to a solid support, borne on a cell surface or located intracellularly.
- screening procedures may involve using appropriate cells or cell membranes that express the receptor and that are contacted with a test compound to observe binding, or stimulation or inhibition of a functional response.
- the functional response of the cells contacted with the test compound is then compared with control cells that were not contacted with the test compound.
- Such an assay may assess whether the test compound results in the generation of a signal similar to that generated by activation of the receptor by proteins of the invention, using an appropriate detection system.
- the proteins of the invention are believed to function by binding to a cell surface divalent cation-dependent receptor such as a C-type lectin receptor and inducing an intracellular signalling pathway, a screening method is likely to function most effectively if it involves the use of receptors on the cell surface, and the monitoring of the induction of an intracellular signal by the binding of the compound to the receptor.
- a cell surface divalent cation-dependent receptor such as a C-type lectin receptor
- a method for identifying an agonist or antagonist compound of the proteins of the invention comprises:
- the compounds to be screened may be contacted with the receptor in the presence of a ligand.
- a ligand may be a lipid, for example cholesterol or a metabolite of cholesterol, such as vitamin D3 or dexamethasone.
- a method of identifying an antagonist compound of the protein of the invention comprises:
- any homologue or fragment of the proteins of the invention may be used in the screening methods described above.
- the compounds to be screened and/or the proteins of the invention may be contacted with the receptor in the presence of a ligand.
- a ligand may be a lipid, for example cholesterol or a metabolite of cholesterol.
- the conditions indicated above may include the presence of culture medium, the presence of a solution containing a physiological concentration of Ca , and/or a pH of 7-8.
- the detectable signal described above may include intracellular phosphorylation, nuclear localisation, gene expression and/or cytokine release.
- simple binding assays may be used, in which the adherence of a test compound to a surface bearing a C-type lectin receptor is detected by means of a label directly or indirectly associated with the test compound or in an assay involving competition with a labelled competitor.
- competitive drug screening assays may be used, in which neutralising antibodies that are capable of binding the divalent cation-dependent receptor, such as the C-type lectin receptor, specifically compete with a test compound for binding. In this manner, the antibodies can be used to detect the presence of any test compound that possesses specific binding affinity for the receptor.
- a person skilled in the art will be able to devise assays for identifying compounds which act on the cognate receptor of the proteins of the present application.
- a technique which may be used to provide for high throughput screening of compounds having suitable binding affinity to the receptor could readily be identified by those skilled in the art (see International patent application WO84/03564).
- This method large numbers of different small test compounds are synthesised on a solid substrate, which may then be reacted with the receptor and washed.
- One way of immobilising the polypeptide is to use non-neutralising antibodies.
- Bound receptor may then be detected using methods that are well known in the art.
- Purified receptor molecules can also be coated directly onto plates for use in the aforementioned drug screening techniques.
- the present invention also includes the agonists, antagonists and other compounds which are identified by the methods that are described above. These agonists, antagonists and other compounds may be form part of the pharmaceutical compositions described above, and may be used in the methods of treatment described above.
- Figure 1 shows the DNA and amino acid sequence of RaA (SEQ ID NOs: 1 & 2).
- Figure 2 shows the alignment of RaA (SEQ ID NO: 2) with Japanin (SEQ ID NO: 8).
- 61 46.56%
- 26 (19.85%) are strongly similar [:]
- (22) 16.79% are weakly similar [.].
- Figure 3 shows the DNA and amino acid sequence of RaB (SEQ ID NOs: 3 & 4).
- Figure 4 shows the alignment of RaB (SEQ ID NO: 4) with Japanin (SEQ ID NO: 8).
- 73 73 (2.9%) are identical [indicated by *], 30 (21.74%) are strongly similar [:] and 12 (8.7%) are weakly similar [.].
- Figure 5 shows the DNA and amino acid sequence of Rsl (SEQ ID NOs: 5 & 6).
- Figure 6 shows the alignment of Rsl (SEQ ID NO: 6) with Japanin (SEQ ID NO: 8).
- Figure 7 shows the alignment of RaA (SEQ ID NO: 2), RaB (SEQ ID NO: 4), Rsl (SEQ ID NO: 6) and Japanin (SEQ ID NO: 8) and indicates the location of the conserved motifs and features.
- the CXXW motif is shown in italics, the conserved cysteine residues are shown in bold and the asparagine residue of the glycosylation site containing sequence is underlined.
- Figure 8 shows the alignment of RaA (SEQ ID NO: 2), RaB (SEQ ID NO: 4), Rsl (SEQ ID NO: 6), Japanin (SEQ ID NO: 8) and DA (SEQ ID NO: 10) and indicates the location of the conserved motifs and features.
- the CXXW motif is shown in italics, the conserved cysteine residues are shown in bold and the asparagine residue of the glycosylation site containing sequence is underlined.
- FIG. 9 shows Rs, RaA and RaB are present in CHO transfectant supematants
- Figure 10A shows the effect of Rsl, RaA and RaB transfectant supematants on CD86 expression in dendritic cells that have not been treated with LPS.
- Figure 10B shows that Rsl, RaA and RaB transfectant supematants inhibit CD 86 expression in LPS treated dendritic cells
- Figure 11 shows the enhancement of B7-H1 upregulation in LPS treated dendritic cells in response to Rsl, RaA and RaB transfectant supematants
- SEQ ID NO: 1 is the nucleotide sequence of RaA
- SEQ ID NO: 2 is the amino acid sequence of RaA
- SEQ ID NO: 3 is the nucleotide sequence of RaB
- SEQ ID NO: 4 is the amino acid sequence of RaB
- SEQ ID NO: 5 is the nucleotide sequence of Rsl
- SEQ ID NO: 6 is the amino acid sequence of Rsl
- SEQ ID NO: 7 is the nucleotide sequence of Japanin
- SEQ ID NO: 8 is the amino acid sequence of Japanin
- SEQ ID NO: 9 is the nucleotide sequence of DA
- SEQ ID NO: 10 is the amino acid sequence of DA
- SEQ ID NO: 1 1 is the nucleotide sequence of RM
- SEQ ID NO: 12 is the amino acid sequence of RM
- SEQ ID NO: 13 is the nucleotide sequence of AM
- SEQ ID NO: 14 is the amino acid sequence of AM SEQ ID NO: 15 i is the nucleotide sequence of RaC
- SEQ ID NO: 16 i is the amino acid sequence of RaC
- SEQ ID NO: 17 i is a degenerate Japanin-derived forward primer
- SEQ ID NO: 18 i is a vector specific reverse primer
- SEQ ID NO: 19 i is a Japanin-specific reverse primer
- SEQ ID NO: 20 i is a Rsl specific reverse primer
- SEQ ID NO: 21 i is a RaA specific reverse primer
- SEQ ID NO: 22 i is a RaB specific reverse primer
- SEQ ID NO: 23 i is a vector specific forward primer
- SEQ ID NO: 24 i is the full amino acid sequence of Rsl
- SEQ ID NO: 25 i is the full length amino acid sequence of RaA
- SEQ ID NO: 26 i is the full length amino acid sequence of RaB
- SEQ ID NO: 27 i is the predicted mature peptide sequence of Rsl
- SEQ ID NO: 28 i is the predicted mature peptide sequence of RaA
- SEQ ID NO: 29 i is the predicted mature peptide sequence of RaB
- SEQ ID NO: 30 i is the nucleotide sequence of a Rsl synthetic gene
- SEQ ID NO: 31 i is the nucleotide sequence of a RaA synthetic gene
- SEQ ID NO: 32 i is the nucleotide sequence of a RaB synthetic gene
- SEQ ID NOs : 33 -40 represent CXXW motifs
- SEQ ID NO: 41 i is Rsl full length DNA/coding sequence (including the stop codon)
- SEQ ID NO: 42 i is RaA full length DNA/coding sequence (including the stop codon)
- SEQ ID NO: 43 i is RaB full length DNA/coding sequence (including the stop codon)
- SEQ ID NO: 44 i is a Rsl 5' DNA sequence
- SEQ ID NO: 45 i is a RaA 5' DNA sequence
- SEQ ID NO: 46 i is a RaB 5' DNA sequence
- SEQ ID NO: 47 i is a Rsl specific forward primer
- SEQ ID NO: 48 i is a RaA specific forward primer
- SEQ ID NO: 49 i is a RaB specific forward primer
- Example 1 Identification of RaA, RaB and Rsl
- the incomplete amino acid sequence of the proteins RaA, RaB and Rsl, which are related to Japanin were obtained by amplifying Rhipicephalus cDNAs in expression libraries which were prepared in Lambda Zap II (Stratagene). Amplification was performed by means of the polymerase chain reaction (PCR) using a degenerate, Japanin-derived forward primer (SEQ ID NO: 17) in combination with either a vector specific reverse primer (SEQ ID NO: 18) in the case of RaB or a Japanin-specific reverse primer (SEQ ID NO: 19) in the case of RaA and Rsl .
- PCR polymerase chain reaction
- Figure 8 indicates that these five proteins form a distinct cluster within the tick lipocalin family. Their evolutionary relatedness and structural similarity suggest conserved functions.
- the inventors have provided the amino acid and nucleotide sequences of three previously unidentified DC modulatory proteins. Based on sequence homology and alignment studies the inventors have been able to determine a number of motifs and features which may be important for the structure and function of such proteins. These results provide an insight into the workings of such molecules which is likely to be useful in designing further DC modulatory molecules for use in therapy.
- LPS was atrichloroacetic acid-extracted preparation from Escherichia coli 055 :B5 (Sigma, product code L4005).
- Human dendritic cells were generated from peripheral blood monocytes isolated from healthy adult donors. Briefly, Leucocyte cones (National Blood Service, Oxford) were mixed -1 :3 (v/v) with Ca2+/Mg2+-free Phosphate-buffered salt solution (PBS), carefully layered on to Lymphoprep (Axis Shield) and centrifuged at 800g for 30 minutes (at 22°C).
- PBS Ca2+/Mg2+-free Phosphate-buffered salt solution
- peripheral blood mononuclear cell (PBMC) layer formed at the interface between the PBS/Buffy coat mixture and Lymphoprep was carefully collected and washed three times with PBS to remove platelets (each time centrifuging for 10 minutes at 4°C, initially at 400g, then 300g, and finally 200g).
- Monocytes were isolated from PBMC by negative selection using the Easysep Human Monocyte Enrichment kit (Stemcell technologies). PBMC were resuspended in Ca 2 7Mg 2+ -free PBS, and the kit was then used in accordance with the manufacturer's instructions.
- DC-RPMI DC-RPMI 1640 supplemented with 10% fetal calf serum (FCS), 2mM L-glutamine, lOOU/ml penicillin, 100 ⁇ g/ml streptomycin, lOOOU/ml human granulocyte macrophage colony- stimulating factor (GM-CSF) (Gentaur) and 250ng/ml human interleukin 4 (IL-4) (Peprotech EC).
- FCS fetal calf serum
- GM-CSF granulocyte macrophage colony- stimulating factor
- IL-4 human interleukin 4
- Amplification was performed by means of the polymerase chain reaction (PCR) using a gene-specific reverse primer (SEQ ID NOs: 20, 21 or 22) in combination with a vector specific forward primer (SEQ ID NO: 23), and employing the Phusion DNA polymerase (Finnzymes) in accordance with the manufacturer's instructions.
- PCR products were cloned into the pCR Blunt II TOPO cloning vector (Invitrogen) in accordance with the manufacturer's instructions, and ligated plasmid used to transform TOP 10 E. coli cells (Invitrogen), which were then plated on to LB agar.
- Amplification was performed by means of the polymerase chain reaction (PCR) using a gene-specific forward primer (SEQ ID NOs: 47, 48 or 49) in combination with a vector specific reverse primer (SEQ ID NO: 23), and employing the Phusion DNA polymerase (Finnzymes) in accordance with the manufacturer's instructions.
- PCR products were cloned into the pT7Blue cloning vector using the Perfectly Blunt cloning kit (Novagen) in accordance with the manufacturer's instructions, and ligated plasmids used to transform TOP 10 E. coli cells (Invitrogen), which were then plated on to LB agar.
- Synthetic genes optimised for CHO cell expression were generated by DNA2.0 (SEQ ID NOs: 30, 31 and 32). They encode the full peptide sequences of the homologues, as well as a C-terminal extension encoding a linker portion (GG) and a polyhistidine tag (HHHHHH), to facilitate detection and purification. They also include non-coding DNA comprising a 5'-Kozak sequence (to allow eukaryotic expression), and restriction enzyme sites to facilitate subcloning: a 5' BamHIsite and a 3' Notlsite.
- pCDNA3.1 was prepared from parental pCDNA3.1-v5-his C (Invitrogen) by excising the multiple cloning region with BamHI and Notl restriction enyzmes (New England Biolabs), treating with FastAP alkaline phosphatase (Fermenatas) to reduce cell ligation of the vector, and gel purifying the vector backbone using the QIEx II system (Qiagen).
- Synthetic genes were prepared from their carrier plasmids by excising the homologue- encoding regions (including the ozak sequence and polyhistidine tag) with BamHI and Notl restriction enyzmes, and gel purifyingthem using the QIEx II system.
- pDNA3.1-homologue constructs were generated by ligation of excised synthetic genes with prepared pDNA3.1 using T4 DNA Ligase (Fermentas). Ligated DNA was used to transform competent E. coli which were then plated on to LB agar to allow the selection of individual colonies for liquid culture. Plasmid DNA was extracted from these cultures using the QIAprepsystem (Qiagen), and its identity confirmed by sequencing. DNA incorporating the synthetic gene sequences was then used for transfection.
- CHO cells were grown in RPMI supplemented with 10% FCS, 2mM L-glutamine, lOOU/ml penicillin and 100 ⁇ g ml streptomycinunder standard cell culture conditions. For transfection, cells were seeded at an estimated 30-40% into 24 well plates, and cultured overnight. Wells with 80-95% confluency were then selected for transfection. Cells were transfected with pCDNA3.1-homologue constructs, pCDNA3.1-japanin-his (as a positive control), pCDNA3.1-lacZ-his (as a positive control for transfection and a negative control for DC-modulatory activity) or with the transfection reagent only (mock transfection control).
- Transfections were performed with the TransIT2020 reagent (Minis) in accordance with the manufacturer's instructions, using 1.5 ⁇ 1 of reagent and 500ng of plasmid DNA per well. Supernatants were harvested after 72 hours, and either analysed or frozen immediately.
- LDS Lithium dodecyl sulphate
- DTT dithiothreitol
- the membrane was blocked with StartingBlock T20 (PBS) Blocking Buffer (Thermofisher) for 30 minutes at room temperature, rinsed with PBS/0.1% Tween 20, and then incubated overnight at 6°C in anti-pentahis-biotin (Qiagen) diluted 1/1000 in PBS/3% BSA 10 A% Tween 20. It was then washed extensively in PBS/0.1% Tween 20, and incubated for 30 minutes at room temperature in streptavidin-HRP (Jackson Immunoresearch) diluted 1/20000 in PBS/0.1% Tween 20. Further PBS/0.1% Tween 20 washes were then performed, and ECL substrate (GE Lifesciences) applied, prior to exposure of X-ray film to the membrane.
- PBS StartingBlock T20
- Example 8 Dendritic cell modulating activity of homologue transfectant supernatants a Inhibition of CD86 upregulation in response to stimuli
- DC modulatory activity was performed using human monocyte-derived DC generated as previously described.
- DC were cultured in 96-well flat-bottomed tissue culture plates (Corning) in DC-RPMI supplemented with the samples to be screened.
- Transfectant supernatants were added to 10% of total volume, while purified japanin was used at 500ng/ml.
- LPS lOOng/ml
- CD86 expression were assessed by flow cytometry, following staining with anti-human CD86-PE, clone IT2.2 (eBioscience) at a 1/50 dilution.
- DC were treated with transfectant supernatants and LPS as described in 4.1 above.
- Levels of B7-H1 (CD274) were then assessed by flow cytometry, following staining with anti-human B7Hl-PECy7, clone MIH1 (eBioscience) at a 1/100 dilution.
- Flow cytometry was performed using a FACSCanto flow cytometer (Becton Dickinson).
- Jaworski D., Jasinskas, A., Metz, C, Bucala, R., Barbour, A. (2001) Identification and characterisation of a homologue of the pro-inflammatory cytokine Macrophage Migration Inhibitory Factor in the tick, Amblyomma americanum Insect Molecular Biology 10(4), 323-331.
- Prostaglandin E 2 is a major inhibitor of dendritic cell maturation and function in Ixodes scapularis saliva
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011800252204A CN103037890A (en) | 2010-03-23 | 2011-03-23 | Dendritic cell inhibitory proteins from ticks |
EP11711379A EP2550009A1 (en) | 2010-03-23 | 2011-03-23 | Dendritic cell inhibitory proteins from ticks |
JP2013500576A JP2013521819A (en) | 2010-03-23 | 2011-03-23 | Dendritic cell inhibitory protein derived from ticks |
US13/636,469 US9676832B2 (en) | 2010-03-23 | 2011-03-23 | Dendritic cell inhibitory proteins from ticks |
US15/595,387 US20180118795A1 (en) | 2010-03-23 | 2017-05-15 | Dendritic cell inhibitory proteins from ticks |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1004850.2A GB201004850D0 (en) | 2010-03-23 | 2010-03-23 | Proteins |
GB1004850.2 | 2010-03-23 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/636,469 A-371-Of-International US9676832B2 (en) | 2010-03-23 | 2011-03-23 | Dendritic cell inhibitory proteins from ticks |
US15/595,387 Division US20180118795A1 (en) | 2010-03-23 | 2017-05-15 | Dendritic cell inhibitory proteins from ticks |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011117582A1 true WO2011117582A1 (en) | 2011-09-29 |
WO2011117582A9 WO2011117582A9 (en) | 2012-12-06 |
Family
ID=42228190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2011/000419 WO2011117582A1 (en) | 2010-03-23 | 2011-03-23 | Dendritic cell inhibitory proteins from ticks |
Country Status (6)
Country | Link |
---|---|
US (2) | US9676832B2 (en) |
EP (1) | EP2550009A1 (en) |
JP (1) | JP2013521819A (en) |
CN (1) | CN103037890A (en) |
GB (1) | GB201004850D0 (en) |
WO (1) | WO2011117582A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1984003564A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Method of determining antigenically active amino acid sequences |
WO2001058941A1 (en) * | 2000-02-11 | 2001-08-16 | Evolutec Limited | Cytokine activity regulator molecules from tick salivary glands |
WO2003075953A2 (en) * | 2002-03-08 | 2003-09-18 | Eli Lilly And Company | Immunomodulatory polymeric antigens for treating inflammatory pathogies |
WO2006077012A2 (en) * | 2005-01-18 | 2006-07-27 | Genfit S.A. | USE OF LXR LIGANDS FOR THE MODULATION OF DENDRITIC CELLS (DCs) |
WO2010032008A2 (en) * | 2008-09-16 | 2010-03-25 | Natural Environment Research Council | Dendritic cell modulatory molecule |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2236807T3 (en) | 1996-05-18 | 2005-07-16 | Evolutec Limited | MOLECULES OF UNION OF VASOACTIVE AMINES. |
-
2010
- 2010-03-23 GB GBGB1004850.2A patent/GB201004850D0/en not_active Ceased
-
2011
- 2011-03-23 JP JP2013500576A patent/JP2013521819A/en active Pending
- 2011-03-23 CN CN2011800252204A patent/CN103037890A/en active Pending
- 2011-03-23 US US13/636,469 patent/US9676832B2/en not_active Expired - Fee Related
- 2011-03-23 EP EP11711379A patent/EP2550009A1/en not_active Withdrawn
- 2011-03-23 WO PCT/GB2011/000419 patent/WO2011117582A1/en active Application Filing
-
2017
- 2017-05-15 US US15/595,387 patent/US20180118795A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1984003564A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Method of determining antigenically active amino acid sequences |
WO2001058941A1 (en) * | 2000-02-11 | 2001-08-16 | Evolutec Limited | Cytokine activity regulator molecules from tick salivary glands |
WO2003075953A2 (en) * | 2002-03-08 | 2003-09-18 | Eli Lilly And Company | Immunomodulatory polymeric antigens for treating inflammatory pathogies |
WO2006077012A2 (en) * | 2005-01-18 | 2006-07-27 | Genfit S.A. | USE OF LXR LIGANDS FOR THE MODULATION OF DENDRITIC CELLS (DCs) |
WO2010032008A2 (en) * | 2008-09-16 | 2010-03-25 | Natural Environment Research Council | Dendritic cell modulatory molecule |
Non-Patent Citations (43)
Title |
---|
"Remington's Pharmaceutical Sciences", 1991, MACK PUB. CO. |
ANGUITA ET AL., IMMUNITY, vol. 16, 2002, pages 849 - 859 |
ANGUITA, J., RAMAMOORTHI, N., HOVIUS, J., DAS, S., THOMAS, V., PERSINSKI, R., CONZE, D., ASKENASE, P., RINCON, M., KANTOR, F.: "Salpl5, an Ixodes scapularis salivary protein inhibits CD4+ T cell activation", IMMUNITY, vol. 16, 2002, pages 849 - 859, XP002295519, DOI: doi:10.1016/S1074-7613(02)00325-4 |
BANCHEREAU, J. ET AL., ANN N Y ACAD SCI, vol. 987, 2003, pages 180 - 187 |
BERGMAN ET AL., JOURNAL OF PARASITOLOGY, vol. 86, 2000, pages 516 - 525 |
BERGMAN, D., PALMER, M., CAIMANO, M., RADOLF, J., WIKEL, S: "Isolation and molecular cloning of a secreted immunosuppressant protein from Dermacentor andersoni salivary Gland", THE JOURNAL OF PARASITOLOGY, vol. 86, no. 3, 2000, pages 516 - 525 |
CAVASSANI ET AL., IMMUNOLOGY, vol. 114, 2005, pages 235 - 245 |
CAVASSANI K A ET AL: "Tick saliva inhibits differentiation, maturation and function of murine bone-marrow-derived dendritic cells", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 114, no. 2, 1 February 2005 (2005-02-01), pages 235 - 245, XP002573177, ISSN: 0019-2805, [retrieved on 20050125], DOI: DOI:10.1111/J.1365-2567.2004.02079.X * |
CAVASSANI, K., ALIBERTI, J., DIAS, A., SILVA, J., FERREIRA, B.: "Tick saliva inhibits differentiation, maturation and function of murine bone-marrow-derived dendritic cells", IMMUNOLOGY, vol. 114, 2005, pages 235 - 245, XP002573177, DOI: doi:10.1111/j.1365-2567.2004.02079.x |
COLE ET AL.: "Monoclonal Antibodies and Cancer Therapy", 1985, ALAN R. LISS, INC., pages: 77 - 96 |
COLIGAN ET AL.: "Current Protocols in Immunology", vol. 1, 1991 |
FIGDOR, C.G. ET AL., NATURE MEDICINE, vol. 10, no. 5, 2004, pages 475 - 480 |
GORMAN ET AL., PROC. NATL ACAD. SCI. USA, vol. 88, 1991, pages 34181 |
HANNIER ET AL., IMMUNOLOGY, vol. 113, 2004, pages 401 - 408 |
HANNIER, S., LIVERSIDGE, J., STERNBERG, J., BOWMAN, A.: "Characterisation of the B-cell inhibitory protein factor in Ixodes ricinus tick saliva: a potential role in enhanced Borrelia burgdoferi transmission", IMMUNOLOGY, vol. 113, 2004, pages 401 - 408 |
HODGSON ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 421 |
HOVIUS ET AL., VECTOR BORNE AND ZOONOTIC DISEASES, vol. 7, no. 3, 2007, pages 296 - 302 |
HOVIUS, J., RAMAMOORTHI, N., VEER, C., GROOT, K., NIJHOF, A., JONGEJAN, F., DAM, A., FIKRIG, E: "Identification of Salp 15 homologues in Ixodes ricinus ticks", VECTOR- BOURNE AND ZOONOTIC DISEASES, vol. 7, no. 3, 2007, pages 296 - 302 |
JAWORSKI ET AL., INSECT MOLECULAR BIOLOGY, vol. 10, no. 4, 2001, pages 323 - 331 |
JAWORSKI, D., JASINSKAS, A., METZ, C., BUCALA, R., BARBOUR, A.: "Identification and characterisation of a homologue of the pro-inflammatory cytokine Macrophage Migration Inhibitory Factor in the tick, Amblyomma americanum", INSECT MOLECULAR BIOLOGY, vol. 10, no. 4, 2001, pages 323 - 331 |
JONES, NATURE, vol. 321, 1986, pages 522 |
KABAT, J. IMMUNOL., vol. 147, 1991, pages 1709 |
KOHLER, G., MILSTEIN, C., NATURE, vol. 256, 1975, pages 495 - 497 |
KOZBOR ET AL., IMMUNOLOGY TODAY, vol. 4, 1983, pages 72 |
LEBOULLE ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 12, 2002, pages 10083 - 10089 |
LEBOULLE, G., CRIPPA, M., DECREM, Y., MEJRI, N., BROSSARD, M., BOLLEN, A., GODFROID, E.: "Characterization of novel salivary immunosuppressive protein from Ixodes ricinus ticks", THE JOURNAL OFBIOLOGICAL CHEMISTRY, vol. 88, no. 12, 2002, pages 10083 - 10089 |
LIU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 3439 |
QUEEN ET AL., PROC. NATL ACAD. SCI. USA, vol. 86, 1989, pages 10029 |
RIBEIRO ET AL., INFECTIOUS AGENTS AND DISEASE, vol. 4, no. 3, 1992, pages 143 - 152 |
RIBEIRO J.M.C.: "Blood-feeding arthropods: live syringes or invertebrate pharmacologists?", INFECTIOUS AGENTS & DISEASE, vol. 4, 1995, pages 143 - 152 |
SAMBROOK, J. ET AL.: "Molecular Cloning, A Laboratory Manual", 2000, COLD SPRING HARBOR LABORATORY PRESS |
SA-NUNES A ET AL: "Prostaglandin E2 is a major inhibitor of dendritic cell maturation and function in Ixodes scapularis saliva", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 179, 1 August 2007 (2007-08-01), pages 1497 - 1505, XP002573178, ISSN: 0022-1767 * |
SA-NUNES ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 179, 2007, pages 1497 - 1505 |
SA-NUNES, A., BAFICA, A., LUCAS, D., CONRADS, T., VEENSTRA, T., ANDERSEN, J., MATHER, T., RIBEIRO, J., FRANCISCHETTI, I.: "Prostaglandin E2 is a major inhibitor of dendritic cell maturation and function in Ixodes scapularis saliva", THE JOURNAL OF IMMUNOLOGY, vol. 179, 2007, pages 1497 - 1505, XP002573178 |
SKALLOVA A ET AL: "Tick saliva inhibits dendritic cell migration, maturation and function while promotong development of Th2 responses", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 180, 1 May 2008 (2008-05-01), pages 6186 - 6192, XP002573176, ISSN: 0022-1767 * |
SKALLOVA ET AL., JOURNAL OF IMMUNOLOGY, vol. 180, 2008, pages 6186 - 6192 |
SKALLOVA, A., IEZZI, G., AMPENBERGER, F., KOPF, M, KOPECKY, J.: "Tick saliva inhibits dendritic cell migration, maturation, and function while promoting development of Th2 responses", JOURNAL OF IMMUNOLOGY, vol. 180, 2008, pages 6186 - 6192, XP002573176 |
SUBKLEWE ET AL., HUMAN IMMUNOLOGY, vol. 68, no. 3, 2007, pages 147 - 155 |
SUBKLEWE, N, SEBELIN-WULF, K., BEIER, C., LIETZ, A., MATHAS, S., DORKEN, B., PEZZUTTO, A.: "Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib", HUMAN IMMUNOLOGY, vol. 68, no. 3, 2007, pages 147 - 155, XP005917284, DOI: doi:10.1016/j.humimm.2006.12.005 |
THOMPSON, J.D., HIGGINS, D.G., GIBSON, T.J.: "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice", NUCLEIC ACIDS RESEARCH, vol. 22, 1994, pages 4673 - 4680, XP002956304 |
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 |
YU ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 343, 2006, pages 585 - 590 |
YU, D, LIANG, J., YU, H., WU, H., XU, C., LU, J., LAI, R.: "A tick B-cell inhibitory protein from salivary glands of the hard tick, Hyalomma asiaticum asiaticum", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 343, 2006, pages 585 - 590, XP024923514, DOI: doi:10.1016/j.bbrc.2006.02.188 |
Also Published As
Publication number | Publication date |
---|---|
GB201004850D0 (en) | 2010-05-05 |
US20130156778A1 (en) | 2013-06-20 |
US20180118795A1 (en) | 2018-05-03 |
WO2011117582A9 (en) | 2012-12-06 |
EP2550009A1 (en) | 2013-01-30 |
US9676832B2 (en) | 2017-06-13 |
JP2013521819A (en) | 2013-06-13 |
CN103037890A (en) | 2013-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pereira et al. | Impaired in vivo CD4+ T cell expansion and differentiation in aged mice is not solely due to T cell defects: decreased stimulation by aged dendritic cells | |
EP2476435B1 (en) | Immunogenic peptides and their use in immune disorders | |
US20160287665A1 (en) | Dendritic cell modulatory molecule | |
JP7078641B2 (en) | RNA for the treatment of autoimmune diseases | |
Ilic et al. | Trichinella spiralis antigens prime mixed Th1/Th2 response but do not induce de novo generation of Foxp3+ T cells in vitro | |
DE60123238T2 (en) | COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
JP5898260B2 (en) | Use of CD83 in combination therapy | |
WO2018057825A1 (en) | Antigen-specific immune modulation | |
KR101469167B1 (en) | Composition for preventing or treating diseases related to abnormal suppression of regulatory T cell activation comprising bee venom-derived PLA2 | |
JP2000508226A (en) | Method for detecting, identifying, isolating, and selectively labeling and targeting TH1 lymphocytes with LAG-3 protein | |
JP2021503276A (en) | Regulatory T cell epitope | |
Wang et al. | Pre-existing Schistosoma japonicum infection alters the immune response to Plasmodium berghei infection in C57BL/6 mice | |
RU2598247C2 (en) | Modulation of antigen immunogenicity by deleting epitopes recognized by nkt-cells | |
EP2595637B1 (en) | Regulatory immune cells with enhanced targeted cell death effect | |
US20180118795A1 (en) | Dendritic cell inhibitory proteins from ticks | |
Miller et al. | Role of innate immunity in transplantation tolerance | |
CN117441678B (en) | Method for adoptively transferring pemphigus vulgaris animal model | |
CN107896494A (en) | Peptide composition | |
O'Connor | Humoral and cytotoxic effector mechanisms of eliciting protection against Plasmodium sporozoite and liver stage infection | |
Dittel | Mechanisms of T cell receptor antagonism: implications in the treatment of disease | |
Müller | Charakterisierung der Rolle von XIAP in der Modulation des entzündlichen Zelltodes und dessen Konsequenzen | |
Müller | Characterization of the role of XIAP in modulating inflammatory death and its consequences | |
Toker | Targeting Antigen Presenting Cells to Treat Autoimmune Inflammation | |
US20170198026A1 (en) | Compositions And Methods For Treating Tumors And Immune Based Inflammatory Diseases | |
WO2001000679A2 (en) | Methods for inducing t cell non-responsiveness to a tissue or organ graft |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180025220.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11711379 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013500576 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3016/KOLNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011711379 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13636469 Country of ref document: US |